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Abstract 
Neurodegenerative diseases are among the most complex and puzzling 
human disorders and in the last century the number of people affected by 
neurodegenerative disorders is increasing year after year. These devastating 
disorders currently do not have any effective therapies or treatments, thus are a 
social and economic burden for modern society and novel therapeutic strategies 
need to be developed for these disease states. 
Synucleinopathies and tauopathies regroup a wide number of neurodegenerative 
disorders characterized by the presence of abnormal protein aggregates 
respectively composed of alpha-synuclein (ASYN) or tau protein. Several reports 
revealed a consisting overlapping between these two groups of disorders and that 
the interactions between ASYN and tau may be a relevant disease component 
that enhances the pathological cascade and spreads the neuronal damage. 
Budding yeast have been largely used to perform studies on the physiopathology 
of synucleopathies and tauopathies and are a powerful tool for rapid screening 
assays that have resulted in the identification of several promising therapeutic 
drugs and targets. 
In this work we used yeast as a model system to reproduce the synergistic 
cytotoxic effect mediated by the co-expression of the human ASYN and tau 
proteins that recapitulates some of the pathological features observed in patient’s 
brain. The model was used to perform genome-wide screening and high-
throughput assays to identify both genes and natural extracts able to modulate the 
synergistic cytotoxic interactions of ASYN and tau. 
In the end, we were able to identify 5 different S. cerevisiae genomic fragments 
containing a total of 25 different complete genes and 11 natural extracts able to 
interfere with the reported synergistic cytotoxicity. These modulators have the 
potential to be further explored in other appropriate disease models and might be 
relevant for academic groups and companies working on neurodegeneration 
engaged in drug discovery.  
Keywords: Neurodegeneration, alpha-synuclein, tau, yeast, screening.  
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Resumo
As doenças neurodegenerativas representam uma das patologias humanas 
mais complexas e desafiadoras, sendo que no último século o número de pessoas 
afetadas tem crescido anualmente. Estas doenças devastadoras não têm 
atualmente nenhuma terapia ou tratamento eficaz, pelo que são um fardo social e 
económico para a sociedade moderna tornando urgente o desenvolvimento de 
novas estratégias terapêuticas para estes estados patológicos. 
O termo sinucleinopatias agrupa várias doenças neurodegenerativas diferentes 
em que a característica patológica marcante é a presença de agregados fibrilares 
insolúveis da proteína alfa-sinucleína (ASYN), designados por corpos de Lewy, 
em populações específicas de células do cérebro. Este grupo de patologias inclui 
a doença de Parkinson, a demência com corpos de Lewy, a atrofia 
multissistémica, muitos casos de doença de Alzheimer (variante da doença de 
Alzheimer com corpos de Lewy), neurodegeneração com acumulação de ferro 
tipo I, falência autonómica pura, e um subtipo de tremor essencial. Na maioria 
dos casos as sinucleinopatias são doenças idiopáticas, envolvendo mutações 
poligénicas, interações génicas e de estilo de vida. Em 1997 o gene da alfa-
sinucleína foi o primeiro gene que se descobriu estar associado à doença de 
Parkinson. 
De igual forma, as tauopatias representam outro grupo de doenças 
neurodegenerativas caracterizadas pela presença de agregados neurofibrilares 
compostos maioritariamente pela proteína tau anormalmente hiperfosforilada. 
Patologias como a doença de Alzheimer, degeneração lobar frontotemporal, 
demência frontotemporal com parkinsonismo ligado ao cromossoma 17, paralisia 
supranuclear progressiva e a degeneração córtico-basal são exemplos de 
tauopatias. O estado de fosforilação da proteína tau tem um papel central na 
etiologia das tauopatias, contudo um elevado número de mutações no gene tau 
foi também identificado e associado com algumas destas doenças. 
As sinucleinopatias e as tauopatias partilham mecanismos moleculares comuns 
conducentes à neurodegeneração e os processos patogénicos através do qual as 
proteínas ASYN e tau induzem morte celular estão relacionados com auto 
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agregação levando à formação de espécies oligoméricas potencialmente 
citotóxicas que por sua vez conduzem a alterações em vários processos celulares, 
nomeadamente na sinalização celular dependente de cálcio, atividade 
mitocondrial, estrutura do citoesqueleto, sistema de controlo de qualidade de 
proteínas, propagação célula a célula e ativação da resposta imune. Mais ainda, 
recentemente foram descobertas muitas interações diretas e indiretas entre estas 
duas proteínas, sendo de salientar a identificação de toxicidade sinergística 
aquando da co-expressão de ASYN e tau em modelos de mamíferos e de 
levedura. Tendo em conta todas estas analogias na fisiopatologia das 
sinucleinopatias e das tauopatias e a citotoxicidade sinergística entre ASYN e 
tau, estas duas proteínas podem representar um duplo alvo para o 
desenvolvimento de novas abordagens terapêuticas para o tratamento de um 
vasto número de doenças neurodegenerativas. 
Apesar da ausência de um sistema nervoso os modelos de levedura são 
amplamente utilizados para abordagens às doenças neurodegenerativas, tendo em 
conta que muitos dos processos envolvidos na progressão patológica, tais como 
atividade mitocondrial, regulação da transcrição, tráfico intracelular e controlo de 
qualidade de proteínas, são muito conservados entre as leveduras e os humanos. 
Adicionalmente, cerca de 30% dos genes humanos envolvidos no 
desenvolvimento de muitas doenças humanas têm ortólogos funcionais em 
levedura. As células de levedura são também usadas para o rastreio em larga 
escala de bibliotecas de compostos devido a vantagens como a avaliação de 
compostos num ambiente fisiologicamente relevante e a seleção negativa 
imediata de compostos tóxicos ou com baixa permeabilidade membranar. Mais 
ainda, estão disponíveis coleções de estirpes de levedura mutadas por deleção, 
juntamente com coleções de sobre-expressão que constituem ferramentas 
poderosas para ensaios de análise genómica - genome-wide screening. 
No trabalho descrito nesta tese utilizámos a levedura como sistema modelo para 
reproduzir e caracterizar o efeito citotóxico sinergístico mediado pela co-
expressão das proteínas ASYN e tau humanas. O modelo foi depois usado como 
uma ferramenta para a descoberta de genes e compostos que medeiam a interação 
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tóxica entre ASYN e tau, possibilitando a identificação de novos alvos para 
intervenção terapêutica. 
Começámos por promover a expressão de ASYN e tau em levedura a partir de 
um vetor epissomal bi-direcional. Os resultados obtidos mostraram que a 
presença de ASYN afeta a solubilidade da proteína tau, aumentando a fração de 
proteína insolúvel/agregada em associação com um aumento significativo na 
fosforilação de tau nos epítopos patogénicos S396/404, o que se sabe levar à 
formação de agregados de tau insolúveis. Mais ainda, mostrámos que no nosso 
modelo a presença de ASYN conduz ao aumento de agregação de tau no epítopo 
S396/404 via Rim11, o ortólogo de levedura de GSK3B. Estas descobertas estão 
alinhadas com outros relatos em que se provou que o epítopo patológico 
S396/404 é um substrato típico de GSK3B e que a ASYN tem a capacidade de 
estimular diretamente a fosforilação de tau via GSK3B, fazendo parte de um 
complexo heterotrimérico contendo ASYN, tau e GSK3B. Apesar do aumento na 
fosforilação e agregação de tau promovido pela co-expressão de ASYN, não 
foram observadas diferenças sinergísticas no fenótipo de crescimento do nosso 
modelo epissomal de levedura. Contudo, esta foi a primeira evidência que a 
ASYN tem capacidade de induzir a fosforilação e agregação de tau em levedura. 
Avaliámos de seguida o efeito da co-expressão de ASYN e tau em levedura 
recorrendo a uma abordagem experimental diferente, baseada na integração 
estável de uma cópia de cada transgene no genoma da levedura. Neste cenário, 
foi observado um forte efeito citotóxico sinergístico no crescimento da levedura, 
associado com um aumento da fosforilação de tau no epítopo S396/404 e a um 
aumento da fração insolúvel de proteína tau. De salientar que esta citotoxicidade 
sinergística é eliminada aquando da remoção de RIM11, demonstrando que o 
fenótipo obtido é resultante da cooperação entre ASYN e tau. Estes resultados 
sugerem que a hiperfosforilação de tau no epítopo S396/404 mediada por ASYN 
pode dar origem a espécies oligoméricas citotóxicas de tau, uma vez que esta 
citotoxicidade sinergística só é observada na estirpe de levedura que apresenta 
níveis mais elevados de tau fosforilada, em correlação com a presença de tau na 
fração proteica insolúvel. 
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Em resumo, as nossas estirpes de levedura, epissomal e integrativa, recapitulam 
muitos dos aspetos mais relevantes das interações de ASYN e tau na patologia 
humana e são ferramentas poderosas para ensaios de rastreio rápidos. Em 
particular, a estirpe integrativa, que revela um fenótipo sinergístico tóxico devido 
à co-expressão de ASYN e tau, foi usada para a realização de um genome-wide 
screening (GWS) e de um high-throughput screening (HTS) com o objetivo de 
identificarmos genes e compostos que possam futuramente ser alvos para o 
desenvolvimento de novas terapias para doenças neurodegenerativas. 
O GWS foi realizado usando a colecção “Yeast Genomic Tiling Collection Assay 
Ready DNA”, que consiste em cerca de 1500 clones, cada um contendo um 
segmento único do genoma da levedura S. cerevisiae num vetor shuttle (E. coli – 
levedura) e fornecida como uma pool de DNA num tubo único. O GWS resultou 
na identificação de 5 fragmentos genómicos diferentes com um total de 25 genes 
completos que, quando sobre-expressos, têm a capacidade de diminuir 
fortemente a citotoxicidade sinergística mediada por ASYN e tau. Apesar dos 
nossos esforços iniciais para identificar os genes responsáveis por esta 
recuperação de fenótipo não terem sido bem sucedidos, a análise destes 
fragmentos genómicos deve ser alvo de atenção futura com vista a compreender 
quais os genes individuais ou interação de genes que medeia este efeito benéfico. 
O HTS foi realizado utilizando a coleção proprietária LUSOEXTRACT, que 
consiste em 3932 extratos naturais provenientes de 1206 organismos isolados de 
ecossistemas aquáticos e terrestres Portugueses únicos. A análise final do HTS 
resultou em 11 extratos naturais com capacidade para melhorar o efeito 
citotóxico mediado pela expressão concomitante de ASYN e tau, sendo que estes 
extratos devem ser alvo de estudos posteriores neste e noutros modelos celulares 
de doença. 
A identificação de moduladores da toxicidade sinergística mediada por ASYN e 
tau é relevante tanto para grupos académicos que trabalham em 
neurodegeneração como para empresas que desenvolvem programas de 
identificação de novos fármacos. Temos a esperança que os resultados do 
presente trabalho possam no futuro ter um impacto positivo nos doentes, famílias 
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e prestadores de cuidados de saúde que lidam diariamente com a falta de 
alternativas terapêuticas para as doenças neurodegenerativas. 
Palavras-chave: Neurodegeneração, alfa-sinucleína, tau, leveduras, screening.
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Chapter I. Introduction 
1. Brain Diseases
1.1. Neurodegenerative Diseases Overview 
According to the Alzheimer’s Foundation of America, dementia is a 
general term that describes a group of symptoms—such as loss of memory, 
judgment, language, complex motor skills, and other intellectual functions 
caused by the permanent damage or death of the brain's nerve cells, or neurons. 
The group of disorders causing dementia includes Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), dementia with Lewy 
bodies (DLB), frontotemporal dementia (FTD), frontotemporal lobar 
degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL). AD is the most common cause of dementia in 
people over 65 and represents about 60% of all dementias, whereas vascular 
dementia caused by stroke or blockage of blood supply accounts for about 30% 
[1-3]. Epidemiologic studies predict that the number of people with dementia 
will double each 20 years in developed and developing countries, with a rate 
three to four times higher in developing areas than in developed regions, as 
consequence of increased life expectancy and exposure to many other risk factors 
(Figure 1).  
Figure 1: Worldwide dementia prevalence and projection in developed and developing 
countries. A) Red countries have a prevalence estimated to be higher than 5%, which is similar 
to the one estimated in developed countries (in grey). Blue countries have a prevalence of 
dementia lower than 3% while in green countries cases of dementia have been reported but 
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prevalence or incidence are unknown. No information is available from white countries. Red 
spots show locations of families with neurodegenerative disorders causing dementia [3]. B) The 
plot is representative of a study were it was estimated that 24 million people had dementia in 
2001 and this amount will double every 20 years to reach 42 million by 2020 and 81 million by 
2040 [2]. 
Aging is well known to be the greatest risk factor for this group of disorders, 
however the neuronal loss caused by intracellular oxidative stress accumulation 
in elderly peoples is much lower than the one observed in chronic 
neurodegenerative process [4]. All the neurodegenerative diseases are mainly 
characterized by an initial abnormal neuronal activity that progressively leads to 
neuronal cell death [5,6] due to the impairment of many intracellular processes 
including protein degradation and mitochondrial biology [7,8]. Another common 
hallmark of several neurodegenerative diseases is the presence of plaques and 
other atypical protein aggregates composed by normal or mutated disease-related 
proteins with different intra or extra cellular localization. Depending on the 
disease subtype, the distribution of these aggregates can be mainly cytosolic, 
predominantly intranuclear, in the endoplasmic reticulum (ER) or extracellular 
[9], but their direct contribute on the pathology progression is still under debate 
[9,10].  
1.2. Aging Brain: The Biggest Risk Factor in Neurodegeneration 
Neurodegenerative diseases share a common risk factor, the aging of the 
brain. In most cases aging and cognitive decline walk side by side, although the 
molecular mechanisms involved in aging are still unclear. Another important 
issue to address is how the physiological brain aging gives rise to 
neurodegenerative disorders. In normal elderly human population the cognitive 
decline—also called mild cognitive impairment (MCI)—is represented by 
delayed recall of verbal information, regression of working memory, short-term 
memory, reduced spatial memory and processing speed which is the most 
affected, then normal aging people take longer to learn new information [11-15]. 
Other cognitive functions such as long-term memory, implicit memory, attention 
span, vocabulary and verbal knowledge are well preserved during the aging 
process and emotional components of memory seem to be even improved 
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especially in people over 65 [16]. The memory functions compromised during 
aging may be the result of activation changes in the hippocampus and prefrontal 
cortex brain regions as revealed by functional imaging analysis [17,18]. 
Activation of the contralateral hemisphere was also shown in normal aging 
brains, representative of the normal compensatory response known as “loss of 
hemispheric asymmetry” that is lost in MCI and in AD [19]. AD human brains 
revealed an over-time accumulation of protein aggregates together with a 
progressive massive neuronal loss in the medial temporal lobes, in particular in 
the entorhinal cortex in contrast with the normal aging brains where a mild cell 
loss was observed only in the prefrontal cortex (Figure 2). 
Figure 2: Brain structure and pathology progression. In MCI, hippocampus and prefrontal 
cortex are the affected regions marked by neuronal loss accompanied by a diffuse moderate 
presence of amyloid plaques composed by Aβ peptide and neurofibrillary tangles composed by 
tau protein. Remarkable general volume loss and selective neuronal cell death in temporal lobe 
in association with widespread massive presence of protein aggregates was observed only in 
AD human brains [4,20]. 
Loss of synaptic function was also observed in the frontal cortex of normal aging 
brain [21]. Synaptic plasticity is a calcium-dependent function and reduced 
mRNA levels of calcium channel subunits and key proteins in the calcium signal 
pathways have been demonstrated in the aging prefrontal cortex [22]. Several 
microarray studies on human aging brain have been performed to evaluate 
changes in gene expression and in the frontal cortex about 4% of the active genes 
are regulated during the aging process [22,23]. Genes involved in memory, 
learning, synaptic plasticity, vesicle protein transport and mitochondrial function 
were significantly down-regulated while genes involved in stress response, in 
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particular antioxidants, DNA repair and inflammation, were up-regulated (Figure 
3). Thus, age-related molecular changes at several levels expose neuronal cells to 
oxidative stress and biological dysfunction, compromising the entire biological 
systems of the brain. In accordance, the risk of AD onset increases 14-fold from 
the age of 65 to 85, afflicting about 47% of people over 85 [24]. Moreover, the 
presence of abnormal protein aggregates composed of amyloid-β peptides (Aβ) 
in AD, of tau protein in FTLD and of alpha-synuclein (ASYN) protein in PD is 
considered a potential contributory factor [10], but the current animal models do 
not explain the interconnections between aging and diseases onset. 
Figure 3: Aging and neurodegeneration. During the aging process changes in gene 
expression (left panel) might contribute to impaired intracellular pathways rendering the neurons 
more sensitive to several stress insults. This age-dependent neuronal vulnerability may 
represent the link between aging and neurodegeneration [4]. 
2. Neurodegeneration Mechanisms
2.1. Failure of Neural Network 
The early impairment of neural activity plays a crucial role in the 
manifestation of neurodegenerative disorders. The evidence of neural network 
failure is the manifestation of impressive fluctuation in functional abilities–
disabilities within the same day in people affected by neurodegenerative 
disorders which significantly correlate with neuropsychological and 
electrophysiological measures [25-27]. Functional reversible fluctuations could 
be the result of impaired intra–extra cellular processes not related to significant 
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neuronal death, such as molecular signalling, synapses activity, neuronal activity 
and neural network (Figure 4) [28-30]. This thesis is strongly supported by many 
studies in transgenic models expressing normal or mutant proteins related to AD, 
PD, HD or other neurodegenerative diseases. Results obtained showed how 
impaired behaviour and neuronal deficit observed without neuronal loss could be 
restored or prevented upon removal of the diseases related proteins [31-34]. 
Figure 4: Neurodegenerative disorders affect neural activities at many levels. 
Neurodegenerative disorders can disrupt molecular pathways, synapses and local circuits in 
specific brain regions, as well as higher-order neural networks. Abnormal network activities may 
result in a vicious cycle, impairing the integrity and functions of neurons and synapses, for 
example, through aberrant excitation or inhibition [5].
For instance, in AD the cellular mechanisms involved in network failure are the 
ones linked to: 
• Activity-regulated genes such as those encoding for cytoskeletal
proteins, long-term potentiation, memory formation and immediate-early
proteins forming the transcription factor AP-1 [35-39].
• Cell membrane receptors including cell adhesion proteins, glutamate
receptors, nicotinic acetylcholine receptors and NMDA receptors [35,40-
44]. 
• Signalling cascades regulated by several kinases and phosphatase like the 
mitogen-activated protein kinase superfamily (MAPKs), cyclin-dependent 
kinase 5 (CDK5), tyrosine kinases (TKs), calcineurin phosphatase and 
striatal-enriched protein tyrosine phosphatase (STEP) [35,40,43,45-48].
• Synaptic integrity controlled by presynaptic terminals and postsynaptic
dendritic spines [49-51].
• Neurotransmitter synaptic release via vesicles cycling [52].
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Dysregulation of the described pathways triggers the activation of complex 
compensatory mechanisms that recruit different neuron subtypes to restore the 
normal activity [53,54]. This compensation could explain the slow progression of 
most neurodegenerative disorders and why so many neurons can die before the 
manifestation of relevant clinical symptoms. Progressive failure of these 
compensatory mechanisms may contribute to the remarkable daily fluctuations.  
2.2. Protein Aggregation and Degradation 
The cellular environment is composed by millions of proteins packed in 
their respective subcellular compartments. Maintaining a proper protein 
homeostasis under intrinsic and environmental conditions is essential for long-
term cells health and to preserve the correct biological functions. Protein 
homeostasis involves transcription regulation, translation, folding, trafficking, 
processing, assembly–disassembly, localization and degradation. Many 
neurodegenerative diseases are characterized by the accumulation of misfolded 
proteins in insoluble inclusions with different anatomical distribution depending 
on the disease (Figure 5) [55].  
Figure 5: Anatomical location of protein aggregates. Macroscopic and microscopic changes 
observed on the most common neurodegenerative disorders [55]. 
AD and PD are respectively the first and second most common age-related 
neurodegenerative diseases characterized by the presence of protein aggregates. 
In AD the extracellular amyloid plaques are generated from the sequential 
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cleavage of the amyloid precursor protein (APP) by β-secretase and γ-secretase, 
giving rise to Aβ peptides of 40 and 42 amino acids residues called Aβ40 and 
Aβ42 [56-58]. Numerous heritable mutations in the APP are linked to AD onset 
during the first fifth decade of life, while the majority of the sporadic cases of 
AD develop clinical onset in people of 70 years old or more [24]. The other 
major hallmark in AD is the presence of neurofibrillary tangles (NFTs) which are 
intracellular insoluble fibrillar deposits formed by hyperphosphorylated tau 
protein [59,60]. Furthermore, more than 50 different mutations in the 
microtubule associated protein tau (MAPT) gene have been associated to familial 
forms of frontotemporal dementia with Parkinsonism linked to chromosome 17 
(FTDP-17) [61,62]. PD is characterized by the presence of Lewy bodies (LB) 
which are intracellular cytoplasmic aggregates composed by the presynaptic 
ASYN protein and the cells affected are mainly the dopaminergic neurons in the 
substantia nigra [61]. The majority of PD cases are sporadic, however duplication 
and triplication of the synuclein-alpha (SNCA) locus  gene  as well point 
mutation in the ASYN proteins (A30P, E46K and A53T) have been identified in 
early-onset PD patients [63,64].  
All these aggregates are composed by misfolded or unfolded disease-related 
proteins organized in a well-defined structure or amorphous, in both cases 
insoluble and refractory to proteolysis [65]. It is currently known that genetic 
mutations, environmental factors and different stress conditions are all able to 
induce protein misfolding and aggregation (Figure 6).  
Figure 6: Misfolding and aggregation. Protein aggregation is a natural phenomenon occurring 
in living organisms, although in several neurodegenerative disorders the disease related 
proteins start to self-aggregate in oligomeric intermediates that evolve into fibrillar structures. 
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Misfolding and aggregation can be promoted by genetic mutations, intra–extra cellular 
concentration, abnormal post-translational modification, proteolyitic cleavage, aging and 
environmental factors [66,67]. 
Recent studies revealed that those protein aggregates may diffuse from one 
affected cell to one normal cell, acting as seeds to initiate protein misfolding and 
aggregation in a process knew as “prion-like diffusion” [68]. In general it seems 
that the aggregation ability correlates with the cytotoxicity, but the direct 
implication of soluble monomer, oligomers or larger protein aggregates with the 
pathology progression is still under debate [69-71]. Several contrasting results 
have been observed and produced in the last century since Alois Alzheimer in 
1907 discovered for the first time the presence of amyloid plaques in post-
mortem brains from demented patients [72]. Two early hypotheses have been 
formulated to correlate neurodegenerative diseases with proteins aggregates: A) 
human neurodegenerative disease causes fibrillar deposits, but protein 
aggregation has no causal role; B) fibrillar protein deposits cause 
neurodegenerative disease. Several evidence argues against both hypotheses, as it 
was observed that some subtypes of neurodegenerative disorders are 
characterized by the absence of protein aggregates, as happens in the genetic 
prion disorder Gerstmann–Straussler syndrome, in sporadic ALS and in 
autosomal recessive juvenile parkinsonism (AJPR) [73-75]. Furthermore, 
dissociation between the severity of the symptoms and the number and the size of 
amyloid deposits in post-mortem AD brains was proved [76,77], and amyloid 
plaques were also found in non-demented elderly peoples [78]. Contrasting 
results have also been produced in neurodegenerative models where, in some 
cases, symptomatic reversal occurs upon removal of the aggregation-prone 
proteins and correlate with the disappearance of intracellular tangles [79-81] 
while in other cases fibrillary deposits are not directly related to diseases 
symptoms [82-84]. Moreover, amyloid fibrils can continue to grow and 
multimerize to form larger aggregates that evolve into an aggresome. It has been 
suggested that the aggresome is a protective structure formed to regroup potential 
proteasome-resistant toxic aggregates that will be then eliminated by autophagy 
[65,85]. However, even if it is not currently possible to directly correlate the 
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amount of a discrete protein aggregate to a human disease, the intracellular 
pathways involved in the maintenance of a proper protein homeostasis are largely 
studied as potential therapeutic targets for the treatment of neurodegenerative 
disorders. The first line of defence against misfolded proteins prone to 
aggregation are the molecular chaperones that can stabilize or refold such protein 
species and are also associated with the protein quality control (PQC) system in 
order to promote the elimination of those proteins that can no longer be refolded 
[86-90]. The PQC is regulated by two main distinct pathways, the ubiquitin-
proteasome system (UPS) and the autophagosome-lysosome pathways (ALP). 
The successive failure of these protein degradation pathways, as cause or 
consequence of early pathological alterations in affected neurons, might represent 
a key step in the pathological cascade that gives rise to spreading 
neurodegeneration. Within the UPS pathway the key structure is the proteasome, 
a barrel-shaped multiprotein complex able to hydrolyse not only cytosolic and 
nuclear soluble proteins but also misfolded proteins inside the ER through a 
process known as endoplasmic-reticulum-associated degradation (ERAD) 
(Figure 7) [91,92].  
Figure 7: UPS system. Proteasomal degradation is ubiquitin (Ub) dependent. Proteins tagged 
with chains of four or more ubiquitins are shuttled to the proteasome by various proteins. The 
ubiquitin conjugation requires three different subtypes of enzymes: the ubiquitin-activating 
enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin-ligase enzyme (E3). In the 
proteasome, proteins are hydrolysed to peptides, which are then released into the cytosol and 
further broken down by peptidases [93].  
The target signal for protein degradation is the presence of a chain composed by 
four or more ubiquitin molecules covalently bound at the C-terminal region [93]. 
The polyubiquitinated targeted proteins need to be unfolded to pass through the 
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proteasome barrel pores to be hydrolysed, thereby oligomeric and aggregated 
proteins are resistant to UPS clearance [87]. Most of the proteins involved in 
neurodegeneration, such as ASYN or tau, are UPS dependent for their clearance 
before they start to self-aggregate [9,91]. When a cytosolic aggregation-prone 
protein becomes a poor proteasome target the ALP pathways succeed as major 
clearance route. Three different types of autophagy (literally self-eating) have 
been described: macro-autophagy, micro-autophagy and chaperone-mediated 
autophagy (CMA) (Figure 8). The components degraded by these roots may 
range from entire organelles, such as damaged mitochondria, to proteins 
aggregates, soluble peptides or microbes that can be specifically or non-
specifically targeted [94].  
Figure 8: Autophagic pathways: In macro-autophagy the cytosolic components to be 
degraded are included in double layer vacuoles called autophagosome that then fuse with a 
lysosome, giving rise to an autolysosome, where the intracellular components are degraded by 
acid hydrolases. Micro-autophagy is characterized by the direct engulfment of the intracellular 
components to be degraded by the lysosome itself. In CMA only soluble proteins are degraded 
by the lysosome, the internalization occurs via the lysosomal-associated membrane protein 
LAMP-2A receptor and an accessory chaperone, the heat shock cognate protein Hsc70 [95-97]. 
Each autophagy pathway has individual characteristics, but they all appear to be 
interconnected and display compensatory up-regulation upon failure of one of 
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them. Cells respond to a blockage of CMA by activating macro-autophagy in a 
constitutive manner [98] while CMA is enhanced when macro-autophagy is 
dysfunctional [99]. The macro-autophagy pathway plays a critical role in the 
selective elimination of aggregated proteins in mammalian cells, a process 
known as aggrephagy in which exclusive proteins are required for substrate 
selection and targeting [88,89].  
In summary, a common hallmark in many neurodegenerative diseases is the 
presence of intra or extra-cellular protein aggregates. All these proteins are 
degraded by UPS and/or ALS pathways, but persistent high intracellular proteins 
levels, post-translational modification, mutations or self-aggregation might 
render them resistant to the UPS-ALS mediated proteolysis, creating an 
inhibition–accumulation loop that can promote aggregation. Although, the PQC 
efficiency undergoes an age-dependent reduction and only a small fraction of 
elderly people develop PD or AD with the presence of intracellular protein 
aggregates, suggesting that other mechanisms are involved in maintaining a 
proper protein homeostasis.  
2.3. Mitochondrial Dysfunction and Oxidative Stress 
Mitochondria are key regulators of cell survival and death [100], play a 
central role in aging and interact with many specific proteins implicated in 
genetic forms of neurodegenerative diseases. Mitochondria possess many copies 
of their own circular DNA (mtDNA) that encode for 13 components of the 
respiratory chain, 2 rRNAs and 22 tRNAs to support the intra-mitochondrial 
protein synthesis [101]. Inherited mutations in mtDNA cause a variety of 
diseases affecting tissues with high energy requirements such as brain and 
muscles and it is well established that mtDNA accumulates mutations and large-
scale deletions with aging that correlate with decline of mitochondrial function 
[100,102]. Mitochondrial insults, including oxidative damage itself, can cause 
imbalance between net production and removal of reactive oxygen species 
(ROS), resulting in ROS accumulation [103]. ROS encompass variety of partially 
reduced metabolites of oxygen such as superoxide anions, hydrogen peroxide and 
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hydroxyl radicals which are generated as by-products of cellular metabolism, 
primarily in the mitochondria. When cellular production of ROS overwhelms its 
antioxidant capacity, damage to cellular macromolecules such as lipids, protein, 
and DNA may ensue [104]. Several enzymatic and non-enzymatic defence 
pathways are involved to prevent the accumulation of ROS. These defence 
mechanisms are not always adequate to counteract the production of ROS, 
resulting in what is termed a state of oxidative stress [105]. Oxidative stress has 
been implicated in a wide variety of disease processes including 
neurodegenerative disorders and is believed to be a major factor in aging [106]. 
At the cellular level, oxidant injury elicits a wide spectrum of responses ranging 
from proliferation to growth arrest, senescence or cell death [105]. Thus, 
mitochondrial accumulation of mutations and net production of ROS might 
contribute to the physiological decline and aging-related neurodegeneration. 
Many neurodegenerative diseases are characterized by mitochondrial 
dysfunctions, displaying increased oxidative stress, decreased synaptic activity, 
reduced energy supply, impaired turnover, defective transport, fragmentation and 
cell death mediated by activation of the apoptotic cascades upon cytosolic release 
of cytochrome c and other pro-apoptotic mediators (Figure 9) [107-114].  
Figure 9: Mitochondrial dysfunctions are associated with several genes related to 
neurodegenerative disease. Impairment of mitochondrial functions and activity leads to 
increased production and accumulation of ROS, mtDNA mutations accumulation, cytochrome c 
release with subsequent apoptosis activation, cell death and neurodegeneration [115].  
Therefore, mitochondrial biology holds a central role in the neurodegenerative 
disorders progression, hence net ROS turnover and energy supply are key events 
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to maintain a proper neuronal activity and cell survivor is strictly dependent on 
their integrity.  
2.4. Neuroinflammation 
Patient brains affected by many different chronic neurodegenerative 
disorders show increased levels of pro-inflammatory molecules as a consequence 
of immune response activation [116-122]. The immune response can be divided 
in innate and adaptive. In the central nervous system (CNS) the innate immune 
response is mediated by the resident macrophages called microglia. The main 
function of these cells is to contrast infections caused by bacteria or virus and 
remove necrotic and apoptotic cells [123]. The effector cells of the adaptive 
immune response are the T cells. Together with microglia, T cells can help to 
recover brain damage during neurodegeneration trough a mechanism that still 
remains unclear [124]. However, impeded microglia activity or persistent 
microglia activation leading to a systemic inflammation may contribute to 
neuronal damage (Figure 10).  
Figure 10: Microglia-mediated neuron damage. In response to disease-specific stimuli, such 
as protein aggregates, microglia can become deleteriously activated to produce a catalogue of 
factors, like ROS and cytokines that are toxic to neurons. Neuronal damage/death can also 
activate microglia to produce these toxic factors. This continual and self-perpetuating cycle of 
neuronal damage/death followed by microglial activation is commonly called reactive 
microgliosis and may be an underlying mechanism of the progressive nature of diverse 
neurodegenerative diseases [125].  
In normal conditions T cells activity is repressed by both microglia and neuronal 
cells, while activated microglia and damaged neurons lose the ability to suppress 
the inflammation response [126]. The innate immune response cells recruit the 
adaptive immune cells by secreting various cytokines and by expressing co-
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stimulatory molecules. Not only micro-organisms but also endogenous signals 
coming from damaged or stressed tissue (danger-associated molecular patterns, 
DAMPs) can activate the immune response within the CNS interacting with the 
Tool-like receptors (TLRs) expressed by the microglia cells [127]. Some 
DAMPs, including heat shock proteins, chromatin, ATP and modified or 
misfolded proteins have adjuvant and pro-inflammatory activity [128]. Notably, 
both ASYN monomers and tau oligomers are able to induce microglia activation 
and T cells proliferation [129,130]. Moreover, microglia does not appear to be 
involved in the removal of protein aggregates or degenerating synapses despite 
its phagocytic potential [131,132] and preventing the microglia proliferation 
leads to a delay in the onset behavioural symptoms and prolonged survivor [133]. 
Animal models of chronic neurodegeneration to deeply study the effects of a 
persistent inflammation are still missing. However, in the murine prion disease 
characterized by the accumulation of misfolded protein, microglia is persistently 
activated as a result of many factors which may include loss of inhibitory contact 
with neuronal ligands, accumulation of misfolded proteins, presence of neuronal 
debris and other unidentified routes [134]. It is clear that systemic inflammation 
is a contributor factor in neurodegeneration [135], thus the use of anti-
inflammatory drugs might be a reasonable therapeutic approach to contrast the 
disease progression.  
2.5. Neuronal Loss 
Impaired intra–extra cellular processes are the prelude of neuronal cell 
death in chronic neurodegenerative diseases. Many evidences of activated 
programmed cell death (PCD) pathways have been collected from post mortem 
brain analysis of patients affected by neurodegeneration [136-139]. PCD plays an 
important role in the development of nervous system and three different forms of 
PCD have been described: apoptotic, autophagic and cytoplasmic [140-143]. 
These different pathways are activated in response to critical events and 
neurodegenerative diseases are associated with insults able to activate suicide 
mechanisms such as accumulation of misfolded proteins, DNA damage, ER 
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stress, inflammation or mitochondria damage [144]. Apoptotic pathways are 
largely investigated in neurodegeneration, in particular in diseases characterized 
by the accumulation of misfolded protein aggregates (Figure 11).  
Figure 11: Apoptotic pathways. Three distinct mechanisms are known to trigger apoptotic 
activation: (1-extrinsic) a death receptor–ligand mediated pathway, (2-intrinsic) a 
mitochondrial pathway involving the production of active caspases and (3-ER mediated) an 
endoplasmic reticulum-mediated pathway [144].  
The ER is the central organelle for the biogenesis and trafficking of membrane 
and secretory proteins. It primarily serves as a cellular adaptive mechanism, 
activating cellular pathways that increase the chaperones mediated protein-
folding capacity and reducing the protein influx into the ER by inhibiting gene 
expression at multiple levels [145]. Proteins that fail to achieve proper 
conformation are removed from the ER through the ERAD process [146]. 
Accumulation of misfolded proteins, inhibition of protein degradation or other 
insults to the ER lead to ER stress, which activates the unfolded protein response 
(UPR) [147]. Prolonged ER stress or defective UPR mechanisms, result in the 
activation of apoptotic suicide mechanisms contributing to the progression of 
neurodegenerative pathologies associated with misfolded proteins [9,91,93,148-
150]. Misfolded proteins are also able to aggregate in oligomers and fibrils that 
interact with many critical cellular targets related to PCD activation. For 
instance, the disease associated ASYN and Aβ proteins are both able to promote 
cell death through apoptosis and flogistic processes activation [151-156]. 
Autophagic PCD represents another important aspect linked to cell death in 
neurodegenerative disorders. It was initially described as a cell death mechanism 
but in the latest years many studies revealed how this pathway is essential for 
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survival when cells are exposed to a wide variety of stress insults including 
nutrient deprivation, growth factor withdrawal, oxidative stress, infection, and 
hypoxia [157]. Besides the autophagy pro-survivor function, a persistent 
activation of this pathways leads to cell death by initiation of a self-digestion 
process. In progressive neurodegenerative disorders the aggregation and 
accumulation of misfolded proteins in intra and/or extra cellular aggregates 
correlates with an abnormal accumulation of intracellular autophagic vacuoles 
(AVs)—index of impaired autophagy—in degenerating cells. The direct 
contribution of the disease related Aβ or tau proteins to impaired autophagy is 
still under investigation, however impaired autophagy initiation in AD brains has 
been described [158] and in neurodegenerative models autophagy inhibition 
leads to intracellular Aβ accumulation [159]. Moreover, a defective lysosomal 
clearance of autophagic substrates due to impaired transport of AVs to lysosomes 
in association with NFTs deposits has been also established [160,161]. 
Duplication or triplication of the SNCA locus gene is sufficient per se to cause 
PD [64] and ASYN overproduction directly impairs autophagy blocking the 
formation of omegasomes which are the autophagosome precursors [162]. 
Specific ASYN post-translational modifications and mutations are also able to 
inhibit the CMA pathway by blocking the substrate internalization into the 
lysosome and thus the subsequent degradation [163,164]. Moreover, an indirect 
autophagy inhibition has also been revealed in the autosomal-recessive form of 
early-onset PD related to impaired mitochondria turnover [165,166]. Hence, 
impaired autophagic response might render cells more sensitive to stress 
conditions inducing cell death [167,168]. In general, complex relationships 
between autophagy and cell death have been described and in neurodegenerative 
disorders the specific factors that make autophagy neuroprotective rather than 
neurotoxic or how impaired autophagy leads to cell death are still enigmatic.  
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3. The Role of ASYN in Neurodegeneration
3.1. ASYN Structure and Function 
The SNCA gene is located on chromosome 4q21 and encodes for a 140 
amino acid protein called ASYN. ASYN has been defined as “natively unfolded” 
because it does not have a defined secondary structure in aqueous solution, 
although it can assume a α-helical secondary structure upon binding to negatively 
charged lipids such as the phospholipids present on cellular membranes [169]. 
The ASYN protein can be divided in three distinct regions: A) amino terminus 
region, from 1 to 60 amino acid residues, containing the apolipoprotein lipid-
binding motifs, which forms the α-helical structure, B) central hydrophobic 
region, from residues 61 to 95, also called non-Aβ component (NAC), which 
confers the β-sheet potential and C) carboxyl terminus region, negatively charged 
and unfolded prone (Figure 12) [170].  
Figure 12: ASYN protein structure and disease-related mutations. The peptide structure 
can be divided in three main regions, A) amino terminus region, B) NAC region, necessary for 
aggregation and C) carboxyl terminus region.  
Two different ASYN alternative transcript variants exist but their physiological 
role remains unclear [171-173]. The synuclein family group includes ASYN 
together with β-synuclein and γ-synuclein and all of them are mainly expressed 
in the brain, generally localized in the presynaptic terminals. The protein 
structure is similar for all, except for ASYN which is the only one possessing the 
NAC region [174]. Some evidence exists about the role of β and γ-synuclein in 
neurodegeneration [175-177], but a detailed characterization to further assess 
their potential contribution to neurodegenerative disease progression is still 
needed. ASYN is highly expressed in the CNS accounting for about 1% of total 
cytosolic proteins and it is actively transported from the cell body, along axons, 
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to synaptic termini [178,179]. Small amounts of ASYN protein have been 
detected also in glial cells [180], while abundant amounts of ASYN protein are 
detectable in erythrocytes and platelets but the physiological function exerted in 
these cells remains unknown [181]. During the neuronal cell development ASYN 
expression is progressively induced depending on the neuronal phenotype, 
however ASYN localizes to the presynaptic terminals only in a later stages of 
synaptic development, while it is absent when they first form [182-184]. 
Moreover, ASYN expression is modulated in critical conditions altering the 
synaptic plasticity or leading to injury [183,185,186], it is implicated in the size 
regulation and amount of the presynaptic vesicular pool and might have a 
chaperone activity to other presynaptic membrane proteins [187-189]. The main 
function of ASYN appears to be the control of neurotransmitter release by a 
chaperone-like function, in synergy with CSPα, in the assembly of SNARE 
complex (Figure 13) [188,190]. 
Figure 13: Role of ASYN and CSPα in the synaptic vesicle cycle. a) Binding of the carboxyl 
terminus of ASYN to the amino terminus of synaptobrevin (VAMP) primes subsequent SNARE 
complex assembly. b) Binding of Hsc70 to SNAP-25 recruits SGT and CSPα to form a 
chaperone machine that promotes a SNAP-25 conformation compatible for SNARE complex 
formation. c) SNARE complex assembly drives membrane fusion and neurotransmitter release 
[191]. 
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The SNARE proteins (Soluble NSF (N-ethylmaleimide-sensitive fusion protein) 
Attachment protein REceptor) consist of more than 60 members and are essential 
for the fusion of synaptic vesicles with the presynaptic membrane [192]. In 
neuronal cells the formation of the assembled complex is a critical step to 
mediate the neurotransmitter release through interactions between SNARE 
proteins localized on vesicles and those on target membranes [193]. Besides the 
regulation of neurotransmitter release, because of its membrane binding ability 
and association with synaptic vesicles, it is possible to assume that ASYN might 
be also involved in endo or exocytosis mechanisms, essential for neuronal 
function and survival.  
3.2. ASYN Implications in Neurodegenerative Diseases 
The term synucleinopathies regroups different neurodegenerative 
disorders characterized by the presence of insoluble fibrillary aggregates of 
ASYN protein, called LB. The distribution of the pathology at the cellular and 
regional level is different in each disease. This group of disorders includes PD, 
many cases of AD (called LB variant of AD), multiple system atrophy (MSA), 
DLB, neurodegeneration with brain iron accumulation (NBIA) type I, pure 
autonomic failure (PAF) and a subtype of essential tremor [194,195]. In most 
cases, synucleinopathies are sporadic diseases caused by multifactorial processes 
in which genetic, environmental and lifestyle factors culminate in overall risk 
[196,197]. The first link between PD and genetic defects was proved in 1997 
when the mutation G209A in the SNCA gene, resulting in an A53T amino acid 
change in the ASYN protein, was associated with autosomal-dominant familial 
cases of early-onset PD in Italian and in some Greek kindred [198]. Later, two 
more mutations in the SNCA gene corresponding to A30P and E46K amino acid 
changes [199,200], together with duplication or triplication of the SNCA locus 
and Rep1 microsatellite expansion, were associated with autosomal-dominant 
forms of familial PD [64,201-203]. 
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3.2.1. ASYN Expression 
The correlation between ASYN protein levels in synucleinopathies 
pathogenesis arises from the association of SNCA gene duplication or triplication 
and REP-1 polymorphisms, which leads to increased SNCA transcriptional 
activity, with familial forms of PD. Little is known about the mechanisms 
involved in SNCA transcription regulation. Recently, a signalling pathway 
involving the ERK/PI3 kinases that mediates the SNCA transcriptional activity 
has been identified [204,205]. Is has also been reported an ASYN-mediated 
sequestration from the nucleus of the methylation factor Dnmt1 leading to 
decreased SNCA methylation and enhanced transcription creating a feed-forward 
loop [206]. Epigenetic factors are also involved in SNCA transcription regulation 
and abnormal SNCA gene methylation, causing enhanced SNCA expression, has 
been observed in PD brains [207,208]. Familial point mutations in the SNCA 
gene are also involved in SNCA expression. It has been observed that the 
expression of mutant alleles is suppressed over time through mechanisms 
involving histone methylation and in particular the presence of the A53T 
mutation enhances the expression of the wild-type allele in a compensatory 
manner. Nevertheless, the total levels of ASYN mRNA are above the normal 
controls suggesting, in this case, that enhanced wild-type ASYN expression is 
responsible for the disease [209-211]. Moreover, in synucleinopathy models, 
when ASYN is phosphorylated in S129 it preferentially localizes to the nucleus, 
reducing the histone acetylation affecting the general mechanisms of gene 
transcription and promoting neurodegeneration [212-214]. There is a general 
agreement that ASYN causes neurodegeneration through a gain-of-function when 
it exceeds a certain level. Concordantly, ASYN protein levels are increased in the 
substantia nigra of aging brains and a significantly increased SNCA expression 
was observed in surviving nigral neurons coming from PD brains [215,216]. 
However, in synucleinopathies models, neurotoxic effects can occur upon a 
severe reduction of ASYN protein levels [217,218]. Hence, the loss-of-function 
as consequence of the endogenous ASYN sequestration by oligomerization and 
inclusions formation causing neuronal damage and in particular, impaired 
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synaptic neurotransmitter release, might be involved in synucleinopathies 
progression as well. 
3.2.2. ASYN, Aggregation Mechanisms and Clearance 
The presence of LB in synucleinopathies is the final step of ASYN self-
aggregation process, which starts with intracellular ASYN accumulation and 
gives rise to dystrophic neurites, defined as aberrant neuritic sproutings, swollen 
dendrites, and/or swollen axons [219]. The aggregation process starts with the 
formation of soluble oligomeric forms of ASYN protein aggregates in β-sheet 
structure (protofibrils) that gradually become insoluble and evolve into fibrils 
forming mature LB (Figure 14), although the exact neurotoxic soluble and/or 
insoluble oligomeric species still remains to be identified. Persistently increased 
intracellular ASYN protein level can promote the formation of ASYN containing 
aggregates [220]. ASYN oligomerization is also enhanced by interaction with 
other proteins, fatty acids and post-translational modifications such as 
phosphorylation, oxidation, nitrosylation, glycation or glycosylation.  
Figure 14: Electron microscope pictures of ASYN aggregates. a-b) Protofibrils round or 
elliptical shaped. c-d) Fibrils in β-sheets structure amyloid like. e-f) Round shaped LB inclusions 
ASYN containing (ASYN immunohistochemistry is indicated by the arrow in e) [221].  
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Phosphorylation is the most studied modification as in LB there is a conspicuous 
amount of ASYN hyperphosphorylation at S129 [222]. The effects of S129 
hyperphosphorylation on ASYN aggregation and cytotoxicity are still 
controversial [223-227] but currently it seems that hyperphosphorylation in 
S129, together with S87, occurs mainly in mature LB [228]. Besides, ASYN 
phosphorylation in these specific epitopes leads to reduced axonal transport 
speed, as observed for the A30P and A53T mutants, which is a plausible 
explanation for the formation of perikaryal and neuritic aggregates [179]. ASYN 
oxidation is another important modification causing oligomerization. Metal ions, 
dopamine and mitochondrial dysfunctions leading to increased ROS levels all 
drive to ASYN oxidation and oligomerization [229-235]. ROS are also 
associated with the peroxidation of cellular membrane lipids and lipoprotein. One 
of the most important products of lipid peroxidation implicated in the 
pathogenesis of many neurodegenerative disorders is the highly reactive 
aldehyde 4-hydroxy-2-nonenal (HNE) [236-239]. ASYN oxidation mediated by 
HNE generates toxic stable soluble oligomers and inhibits their conversion into 
insoluble fibrils supporting the soluble oligomers toxicity theory [240]. ASYN 
nitration, similarly to oxidation, induces comparable effects promoting fibril 
formation and within the LB there is an extensive accumulation of nitrosylated 
ASYN [241,242]. Another significant ASYN modification is the carboxyl 
terminus truncation that generates aggregation-prone fragments [243,244]. 
Calpain is one of the most important calcium-dependent enzymes involved in the 
ASYN cleavage, both proteins localizes at the presynaptic terminals [245,246] 
and increased intracellular calcium influx mediated by ASYN oligomers could 
generate a feed-forward loop between calpain-mediated ASYN cleavage and 
oligomeric species formation [247,248]. ASYN oligomerization can also occur 
upon interaction with other proteins or fatty acids. The most notable protein-
protein interactions are with tau and synphilin-1 that directly promote ASYN 
aggregation enhancing the formation of insoluble inclusions [249-251]. 
Polyunsaturated fatty acids interact with ASYN as well, enhancing 
oligomerization and neurotoxicity [252,253] and sequestration of the arachidonic 
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fatty acid away from the SNARE complex by ASYN has an inhibitory effect on 
neuronal transmission [254]. In synucleinopathy models based on ASYN variants 
lacking the NAC region, essential for aggregation, no toxic effects have been 
reported [255]. Moreover, protective effects have been observed in 
synucleinopathy models upon treatment with reagents preventing or neutralizing 
ASYN oligomers [256,257] and upon overexpression of heat shock chaperones 
which assist the refolding of aggregation prone proteins [258,259]. Thus, 
contrasting the formation of cytotoxic ASYN oligomeric species might be a 
plausible therapeutic approach to treat patients affected by synucleinopathies. 
Within the cellular environment the appropriate intracellular protein turnover is 
maintained by the UPS, CMA and macro-autophagy pathways, all involved in 
ASYN degradation. Soluble unfolded ASYN monomers are targeted for the UPS 
system and the CMA, whereas ASYN oligomers and ASYN containing 
aggresomes are targeted for macro-autophagy and lysosomal degradation 
[164,260-262]. LB are mainly composed by highly ubiquitinated ASYN protein, 
but also proteasomal subunits, ubiquitinating and de-ubiquitinating enzymes and 
proteasome activators are abundantly present in these aggregates, asserting an 
involvement of the UPS pathway in the clearance of ASYN [263-267]. The first 
evidence of UPS impairment was observed in the substantia nigra of PD brains 
where the proteasomal activity was significantly decreased in comparison with 
age-matched controls [268,269]. This evidence correlates with decreased gene 
expression of several proteasomal subunits only in the substantia nigra and in the 
cortex of patients, while in other brain regions the expression was unchanged or 
even increased [268,270-273]. In synucleinopathy models a direct inhibitory 
effect of ASYN on proteasome activity has been reported in a wide number of 
studies. Persistently increased intracellular ASYN protein levels leads to 
impaired proteasome function creating a vicious circle between UPS impairments 
and ASYN accumulation [154,274-280]. Besides, induced proteasome inhibition 
elicits a dose-dependent neurodegeneration with formation of ubiquitin and 
ASYN positive inclusions [281-283] and acute UPS inhibition was shown to 
induce compensatory clearance pathways by up-regulating autophagic flux 
23
[284,285]. Moreover, by genome wide association studies (GWAS), mutations in 
PARK2 (an E3 ligase also involved in the proteasome activity) and PARK5 (an 
ubiquitin hydrolase) represent a risk factor for monogenic forms of PD [74,286]. 
However, some patients exhibit a normal or enhanced proteasome activity in the 
brain regions affected by the presence of LB, suggesting that region-specific 
perturbation of proteasome function is unlikely to explain the cause of 
neurodegeneration [287,288].  
Together with the UPS system, CMA and macro-autophagy are the two 
compensatory pathways involved in the ASYN clearance that ends with the 
degradation of the targeted proteins inside the lysosomes. In CMA the lysosome 
internalization of targeted proteins occurs via the lysosomal-associated 
membrane protein LAMP-2A receptor [95-97]. Mutant A53T and A30P ASYN 
were shown to strongly bind the CMA receptor LAMP-2A but unable to be 
internalized for degradation, thus acting as CMA inhibitors [163]. A similar 
inhibitory effect on LAMP-2A occurs upon dopamine-induced conformational 
changes in wild-type ASYN [164]. However, contrasting results exist in relation 
to the levels of the CMA receptor LAMP-2A. These were found to be reduced in 
the substantia nigra and amygdala of PD patients and increased in the temporal 
cortex of DLB patients [289,290]. Defective CMA was also observed in familial 
PD patient’s brains carrying mutant LRRK2 protein which interfere with the 
organization of the CMA translocation complex that could results in ASYN 
accumulation and other PD related proteins degraded by this pathway [291]. On 
the other hand, the involvement of macro-autophagy in synucleinopathies was 
first proved by ultrastructural examination of neurons in the substantia nigra of 
PD patients revealing accumulation of AVs, which is consistent with either 
overproduction or impaired vacuoles turnover [292]. This finding was supported 
by increased autophagosome markers and decreased lysosomal markers in 
degenerating neurons, validating the presence of abundant and dysfunctional 
autophagosomes [289,293-297]. Persistent increased intracellular ASYN levels 
are able to inhibit macro-autophagy in a very early stage, blocking the formation 
of omegasomes, which are the autophagosome precursors, via Rab1 inhibition 
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and Atg9 mislocalization [162]. Moreover, lysosomal dysfunctions also affect the 
secretion of ASYN via exosomes [298], which could have implications for the 
cell-to-cell spreading and disease progression [299]. Collectively, all these 
findings show the ability of ASYN to inhibit all the clearance pathways involved 
in the maintenance of a proper intracellular protein turnover, an impairment that 
might be crucial in the pathology progression. Thus, restoring the proper PQC 
system activity could be a plausible approach to arrest or reduce the disease 
spreading. 
3.2.3. ASYN and ER/Oxidative Stress 
In synucleinopathy models, ER stress together with Golgi fragmentation 
leading to cell death is an early event that occurs in concomitance with the 
appearance of ASYN soluble oligomeric species [300,301], arguing that the 
primary target of ASYN-mediated neurotoxicity might be the ER-Golgi 
compartment. The ER-to-Golgi trafficking seems to be impeded through a direct 
ASYN-mediated mechanism, blocking the vesicle docking and fusion at a pre-
Golgi step and inhibiting the assembly of the ER/Golgi SNARE complex 
[302]. The proteins involved in the ER-to-Golgi vesicular trafficking (RABS) 
resulted to be the major class of modulators of ASYN toxicity [303]. 
Hence, in synucleinopathy models overexpression of RABS involved in 
the synaptic vesicular functions, in particular RAB1, prevent the 
dopaminergic toxicity to which neurons are very sensitive [304,305].
The degeneration of dopaminergic neurons in the substantia nigra correlates with 
impaired mitochondrial activity leading to increased oxidative stress and 
consequent cell death. Accumulation of point mutations and deletions in mtDNA, 
causing mitochondrial dysfunctions, have been observed in the brain of 
PD patients [306], while several mtDNA polymorphisms and haplotypes 
are associated with the risk of PD onset [307]. In synucleinopathy models 
ASYN directly interacts with the inner mitochondrial membrane causing 
mitochondrial fragmentation, activity impairment, increased ROS production 
and cell death due to the activation of the apoptotic cascade mediated by the 
mitochondria release of cytochrome c [156,308,309]. Moreover, by GWAS 
studies, mutations in genes 
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required for the mitochondrial activity causing mitochondrial dysfunctions are 
associated with familiar forms of PD [310]. In detail, parkin and PINK1 proteins 
are associated with the mitochondrial outer membrane and prevent cell death by 
inhibiting cytochrome c release and caspases activation [311,312], mutations or 
deficiency cause oxidative stress, selective complex I impairment and altered 
synaptic functions [313]. DJ-1 is mostly localized in the cytosol, but also in the 
nucleus and associated with mitochondria [314]. Its biological implications are 
extremely diverse, it can act as a negative apoptosis regulator [315] or a potential 
ROS scavenger sensor activating neuroprotective pathways [316]. Mutations in 
DJ-1gene are associated with increased oxidative stress and apoptosis [317]. 
HTRA2 is a mitochondrial quality control protein and when released in the 
cytosol acts as a pro-apoptotic factor [8], mutations induce mitochondria swelling 
and decreased membrane potential [318]. Finally, LRKK2 is a protein largely 
present in the cytoplasm but also associated with the mitochondrial outer 
membrane. PD patients carrying the G2019S mutation exhibit reduced 
mitochondrial membrane potential and total intracellular ATP levels 
accompanied by increased mitochondrial elongation and interconnectivity [319], 
suggesting an important role in the regulation of mitochondrial homeostasis. 
Furthermore, specific inhibitors of the mitochondria complex I transport chain, 
such as pesticides and MPTP (1-methyl-4-phenyl-1,2,3,6-teteahydropyridine), 
are also able to induce neurological changes similar to PD, reconfirming the key 
role of mitochondria activity and oxidative stress in the disease progression 
[310]. Hence, restoring the normal mitochondrial activity might be helpful to 
contrast the progressive neuronal loss observed in patient brains. 
3.2.4. ASYN, Cytoskeleton and Synaptic Activity 
The cytoskeleton is a cellular scaffold composed by a network of 
microtubules and plays important roles in both intracellular transport, such as the 
movement of vesicles and organelles, and cell division. ASYN has been shown 
to bind and modulate actin polymerization, thus indirectly affecting intracellular 
trafficking [320]. A direct interaction between ASYN and microtubules has been 
reported in many studies [321] but weather this interaction leads to enhanced or 
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decreased tubulin polymerization is still unclear as conflicting results have been 
reported [322,323]. An indirect negative effect on tubulin polymerization can be 
related to increased ASYN-mediated tau phosphorylation leading to defects on 
the microtubular network assembly [324,325]. Notably, in the case of tubulin 
depolymerisation, free tubulin monomers are able to initiate and promote ASYN 
fibrils formation [326]. In this context, axonal transport defects preceding 
neurodegeneration can be also related to ASYN-mediated abnormal cytoskeleton 
assembly as shown in synucleinopathies models [327].  
Given the physiological role of ASYN in the regulation of neurotransmitter 
release, many models have been created to study the synaptic effects of ASYN-
induced neurotoxicity. The pathological repercussions reported describe a 
general impairment in the neurotransmitter release pathway preceding the 
synaptic and neuritic degeneration. In detail, ASYN overexpression was 
associated with loss of presynaptic proteins, decreased neurotransmitter release, 
redistribution of SNARE proteins, swelling of synaptic vesicles and inhibition of 
vesicle recycling [327-330]. Still, the exact cascade point in which ASYN 
initiates its neurotoxicity is still unknown. However, since the synaptic 
neurotransmitter release is a calcium-dependent mechanism, increased 
intracellular calcium influx mediated by the ASYN oligomers that form pores in 
the cellular membrane might be the starting point [247,248]. In a similar manner, 
synaptic vesicles can be damaged by ASYN oligomers causing cytosolic 
neurotransmitter release that could lead to increased oxidative stress and cell 
death [331,332]. Here, again, cells undergo a self-feeding cascade between 
ASYN oligomers, axonal transport defects, calcium perturbation and cytosolic 
neurotransmitter leakage leading to neurodegeneration. Moreover, as mentioned, 
the calcium-mediated calpain activation that originates carboxyl terminus 
truncated aggregation-prone ASYN fragments could enhance this potential 
vicious circle. 
3.2.5. ASYN Cell-to-Cell Propagation 
Initially ASYN was thought to be an intracellular protein, but now it is 
well known that it can be secreted and uptaken by neighbouring cells. The 
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secretion mechanisms are still unclear but appear to occur via a non-classical 
secretory pathway through exosomes release upon calcium influx [333-335]. On 
the other hand, ASYN uptake is dependent on cell type and on ASYN species. 
Oligomeric ASYN aggregates appear to be easily taken up acting as seeds for the 
fibrillization of endogenous monomers [247,336-338] supporting the “prion-like 
propagation” theory. Interestingly, ASYN propagation has been associated with 
mitochondrial dysfunction as upon intragastric pharmacological inhibition of 
mitochondria complex I,ASYN gradually spreads from enteric cells to neuronal 
cells [339], consistent with early enteric ASYN pathology in PD patients and in 
vivo models [340,341]. Importantly, secreted ASYN can induce inflammatory 
response by glial cells causing cell death and thus enhancing the 
neurodegeneration [342-344]. 
3.3. ASYN Physiopathology in Yeast Models 
Yeast models are largely used to study ASYN induced cell death. The 
yeast S. cerevisiae does not possess any ASYN ortholog, nevertheless this 
organism results to be a powerful tool to uncover important aspects for the 
physiopathology of synucleopathies. The binding of ASYN to the yeast plasma 
membrane is mediated by the interaction between the detergent-resistant 
membrane domains, known as lipid rafts, and the N-terminal ASYN region, 
containing the apolipoprotein lipid-binding motifs. This interplay is fundamental 
for the subsequent inclusions formation, which occurs between the ASYN central 
hydrophobic regions (NAC) interaction [347-351]. Hence, mutations that disrupt 
the N-terminal α-helix formation, such as the ASYN diseased related A30P 
mutant or other mutations that prevent the N-terminal acetylation, preclude the 
membrane interaction and the following self-aggregation process [348-350]. 
When expressed in yeast, the human wild-type ASYN and the mutants A53Tor 
E46K are delivered to the plasma membrane trough the secretory pathway where 
they begin to accumulate [345,346]. The aggregation process starts with the 
appearance of small nuclei that continue to grow over time and then translocate 
to the cytoplasm forming larger aggregates [345,347]. Because of its decreased 
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membrane binding ability, the A30P mutant is mainly diffused in the cytoplasm 
and does not form any inclusions. However, it can be forced to produce 
intracellular aggregates by increasing the lipid synthesis or providing the 
necessary seeds by co-expression with the wild-type ASYN [346]. Moreover, 
some of these larger inclusions are Thioflavin-S positive indicating an 
aggregation status in β-sheets similar to the LB in PD brains, whereas other 
inclusions represent ASYN induced aggregates of cytoplasmic vesicles (Figure 
15) [305,347,348].
Figure 15: A) Expression of α-synuclein in the yeast S. cerevisiae. A) At the beginning, 
wild-type ASYN starts to bind the plasma membrane, small nuclei associated to the plasma 
membrane start to appear after 12 hours that continue to grow over time forming bigger 
cytoplasmic inclusions. B) A30P mutant is located in the cytoplasm and can form inclusions on 
the nuclei provided by wild-type ASYN. C) Thioflavin-S staining confirms the presence of β-
sheeted ASYN aggregates [349]. 
The exact mechanism that initiates ASYN self-aggregation process is still 
unclear and besides the membrane binding ability it might involve other post-
translational modifications such as phosphorylation, nitration or C-terminal 
truncation [242,350-352]. In addition, enhanced oxidative stress seems to trigger 
ASYN oligomerization [353]. In S. cerevisiae cytotoxic effects have been 
observed upon expression of the human wild-type ASYN and the A53T or A30P 
mutants [354], while cytotoxic effects caused by the expression of the E46K 
mutant have been reported only in S. pombe [346]. In yeast models the ASYN 
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mediated cytotoxicity seems to be more dependent on the genetic background, 
the expression levels and the membrane binding capacity rather than on the 
inclusions formation, as in some strains the presence of intracellular aggregates 
does not affect the cell growth ability [347,354-356].  
As observed in PD patient’s brains, the cytotoxic effects mediated by the 
expression of the human ASYN in yeast models are related to vesicle trafficking, 
PQC system defects, oxidative stress enhancement and cell death. To reach the 
plasma membrane from the nucleus through the secretory pathway, the first 
intracellular yeast compartment encountered by ASYN protein is the ER. The 
earlier outcome due to ASYN expression is a block in the ER-to-Golgi vesicular 
trafficking that causes ASYN accumulation within the ER and impaired docking 
and fusion of ER-derived vesicles to the Golgi membrane [304]. The 
consequence of this block is the accumulation of ER-derived vesicles near the 
plasma membrane and defects in the ER retro-translocation of misfolded 
cytoplasmic proteins for proteasomal degradation through the ERAD process 
causing ER stress and PQC impairment [304]. Furthermore, additional toxicity is 
given by hindered endocytosis and secretory pathways because of the obstruction 
of post-vesicles internalization and vacuoles fusion defects [354,357]. The 
involvement of PQC molecular chaperones has been observed using yeast strains 
lacking individual chaperones where the inclusion formation was enhanced when 
compared with the wild-type strain [357]. Results were further reconfirmed in 
other studies showing a protective effect against ASYN induced cytotoxicity by 
chaperones overexpression or pharmacological activation of the heat-shock 
response [309,345,358], resembling the results obtained in other 
synucleinopathies models [259,359-361]. Notably, in yeast cells, ASYN 
expression itself is able to induce the transcription of heat-shock proteins, 
however this induction is not strong enough to be protective when compared with 
the response triggered by thermal stress or pharmacological treatments [345]. An 
involvement of the UPS in yeast models was already evident in the first study of 
yeast PD model, since many ASYN intracellular inclusions were ubiquitin 
positive and proteasome impairment was also observed to be related with ASYN 
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overexpression [354] as the result of an altered proteasome composition in 
addition to a general decreased protein synthesis [274]. The UPS involvement 
was then reconfirmed using specific proteasomal inhibitors or proteasomal 
mutant yeast strains proving that proteasomal inhibition correlates with an 
enhancement of ASYN accumulation and inclusions formation [345,347,355]. To 
compensate the UPS failure or insufficient proteasomal activity, misfolded 
proteins are processed by the autophagic pathway and in yeast, like in 
mammalian cells, the activation of autophagy by the TOR inhibitor rapamycin 
leads to a significant reduction of ASYN inclusions [347]. Therefore, contrasting 
results exist about the role of autophagy in ASYN yeast models as other studies 
reported an increased ASYN mediated cytotoxicity upon autophagy induction by 
rapamycin, probably due to increased levels of soluble toxic ASYN conformers 
[362]. Oxidative stress and cell death are other important aspects of PD 
physiopathology successfully replicated in yeast models. Metal ions are one of 
the major risk factors for PD onset because their ability to induce oxidative stress 
and oligomerization of ASYN [363]. In yeast cells expressing ASYN the 
treatment with ferrous ions leads to increased cytotoxicity related to increased 
inclusions formation and oxidative stress markers such as ROS [347,364] 
together with ASYN-mediated release of typical yeast apoptotic markers such as 
cytochrome c and phosphatidylserine [309]. Taken together, all these results 
summarize a self-amplifying killer loop between ER stress, oxidative stress and 
cell death mediated by ASYN expression that make yeast models a powerful tool 
to identify compounds and genes for potential therapeutic intervention. 
4. The Role of Tau in Neurodegeneration
4.1. Tau Structure and Function 
Tau protein, alias Microtubule Associated Protein Tau, is encoded by the 
MAPT gene located on chromosome 17q21 and consisting of 16 exons 
[365,366]. Tau is a natively unfolded protein especially expressed in neurons 
where its main function is the stabilization and assembly of microtubules (MT) 
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through a direct binding with the tubulin protein [367]. In the CNS six tau 
isoforms exist because of alternative splicing of exons 2, 3 and 10. These 
isoforms differ by the presence or absence of one or two acidic inserts at the N-
terminal domain (exons 2 and 3), and by whether they contain three or four 
repeats (exon 10) of a conserved tubulin binding motif at the C-terminal region 
(figure 16) [366,368].  
Figure 16: Representation of the six different tau isoforms in the central nervous system 
and their amino acid lengths.  
The microtubule binding domain (MTBD) is the region in charge of binding to 
MT. The isoforms with four repeats (4R) possess a higher binding affinity when 
compared to the ones with tree repeats (3R) and in normal human brain the 3R 
and 4R-tau isoforms are equally expressed [369,370]. The binding affinity of tau 
for the microtubule (MT) is principally mediated by its serine/threonine 
phosphorylation status, while hyperphosphorylated tau is unable to interact with 
the MT and starts to self-aggregate [371,372]. Besides the binding properties to 
the MT, tau can also interact with actin affecting its polymerization and thus 
modulating the interaction of actin with MT to achieve the appropriate 
cytoskeleton assembly [373-375]. Given its physiological function in 
cytoskeleton polymerization, tau plays an essential role in maintaining the 
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appropriate cell morphology and, as the MT network is implicated in the axonal 
transport of molecules and organelles, impaired MT assembly can have important 
repercussions on the function and viability of neurons [376]. Moreover, tau can 
interact via its N-terminal region with the plasma membrane and with several 
proteins involved in the signal transduction, suggesting a dual role of tau both as 
substrate or activity regulator [377-381]. For instance, tau can be phosphorylated 
by the Fyn kinase acting as substrate but can also regulate the Fyn activity that is 
connected with the recruitment of both tau and Aβ within the lipids rafts [382- 
385]. Because of the large number of tau interactions implicated in many 
intracellular pathways, ranging from cell morphology to cell signalling, it is still 
hard to uncover the exact mechanisms that are responsible for tau misfolding, 
aggregation and cell death.  
In the last years several mutations in the MAPT gene have been discovered and 
associated with neurodegeneration. In 1994 the first dominant inherited form of 
frontotemporal dementia with parkinsonism linked to the chromosome 17q21-22 
(FTDP-17) was identified in the region containing the MAPT gene, characterized 
by the presence of tau inclusions in nerve cells and/or glial cells [386]. Later, in 
1998, the first mutation in the MAPT gene was discovered [387,388] and so far 
51 different mutations in the same gene have been identified and associated with 
FTDP-17 (Figure 17) [62].  
Figure 17: Pattern of identified mutations and respective exons in the MAPT 
gene associated with FTDP-17 [62]. 
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Mutations in the MAPT gene account for about 5% of all FTDP-17 cases and can 
be divided in two main groups. The first group includes the ones affecting the 
ability of tau to bind the MT promoting tau aggregation, while the second group 
includes the ones causing alternative mRNA splicing leading to an imbalanced 
ratio of 3R/4R tau isoforms, resulting in an overproduction of the 4R-tau 
isoforms [62]. In general, all these mutations seem not to affect the number or the 
position of tau phosphorylation sites suggesting that hyperphosphorylation is not 
the main toxic event in FTDP-17. However, some of them might be 
phosphorylated faster than the normal isoforms [389]. Notably the P301S 
mutation, that greatly reduces tau ability to promote MT assembly, can cause 
different syndromes in the same family e. g. frontotemporal dementia in the 
father and corticobasal degeneration in his son [390]. Furthermore, in the 
European descendent population the MAPT gene possesses two different 
polymorphisms identified by the inversion (H1) or non-inversion (H2) of ∼900 
Kb on chromosome 17q21, spanning the entire MAPT coding region [391,392]. 
By GWAS, the haplotype H1 represents a risk factor for a number of 
neurodegenerative diseases, such as the progressive supranuclear palsy, 
corticobasal degeneration and idiopathic PD [393-403]. On the other hand, the 
haplotype H2 is associated with increased expression of exon 3 suggesting a 
protective effect mediated by the insertion of this exon as the tau isoforms 
containing exons 2,3 and 10 show a decreased aggregation aptitude if compared 
with the tau isoforms containing exons 2 and 10 [404,405]. 
4.2. Tau Implications in Neurodegenerative Diseases 
The presence of NFTs mainly composed by hyperphosphorylated tau is a 
common hallmark in tauopathies, a group of several different neurodegenerative 
diseases of which AD, ALS and FTDP-17 are the most representative (Figure 
18). Tau phosphorylation status plays a central role in the tauopathies etiology 
which is characterized by abnormally hyperphosphorylated tau that gives rise to 
NFTs. Tau phosphorylation is regulated by several kinases and phosphatases 
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which are largely studied as potential targets for therapeutic intervention.
Figure 18: A-B) Neurofibrillary tangles made of tau protein (brown) in chronic traumatic 
encephalopathy (left) and in AD (right). C) Neurodegenerative diseases with tau inclusions 
[62].  
Two major groups of kinases are implicated in tau phosphorylation, the proline-
directed protein kinases (PDPKs) and the non-PDPKs. The first group includes 
glycogen synthase kinase 3 beta (GSK3B), cyclin-dependent kinase 5 (CDK5), 
MAPKs and stress-activated protein kinases (SAPKs). GSK3B and CDK5 are the 
most studied ones as both co-localize with MT and directly phosphorylate tau 
within the intracellular environment [406-411]. Hyperphosphorylation of tau by 
GSK3B inhibits tau mediated MT assembly and promotes the generation of 
potential toxic molecules [412-414]. Like GSK3B, hyperphosphorylation of tau 
by CDK5 promotes dimerization [415] and, interestingly, NFTs have been 
found in the brain regions containing elevated CDK5 activity [416,417]. Moreover, 
CDK5 is also able to affects tau phosphorylation status indirectly [418] which 
occurs, under particular conditions, via a CDK5-mediated inhibition of GSK3B 
[419]. Among the non-PDPKs group, the microtubule affinity regulating 
kinase (MARK) and the cyclic AMP-dependent protein kinase (PKA) are the most 
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important kinases. MARK and PKA phosphorylation motifs are within the tau 
MTBD, when these motifs are phosphorylated tau is released by the MT and the 
ability to self-assemble is decreased as well [420,421]. However, the free MT-
unbounded phosphorylated tau generated by MARK and/or PKA is the starting 
point for the formation of hyperphosphorylated tau forms. Thus, the 
phosphorylation of tau by MARK and/or PKA acts as priming for the 
subsequent action of CDK5 and GSK3B generating the hyperphosphorylated 
tau which is the main component of NFTs [422]. At the beginning it was 
proposed a correlation between neurodegeneration and the presence of NFTs, 
which were thought to be the primary cytotoxic source [423-425]. However, this 
theory is still under debate as contrasting results exist about the relation between 
cell death and NFTs [426], which may even represent a protective mechanism by 
which neuronal cells try to inactivate other toxic species [71,427]. 
4.2.1. Tau, Oxidative Stress and Clearance 
Besides the presence of intracellular protein aggregates, mitochondrial 
dysfunctions and oxidative stress are another important aspect of tauopathies. 
However, the direct repercussion of tau protein on mitochondrial activity is still 
elusive. What is known about the interaction between tau and mitochondria is 
that tau redistribution from the axons to the cell body, together with retrograde 
mitochondria transport and cell death, occurs upon treatment with mitochondrial 
complex I inhibitor [428]. The retrograde transport is a general process for the 
elimination of dysfunctional mitochondria by autophagy with subsequent 
increased ROS levels [429]. In this context it has been proved that increased 
oxidative stress results in hyperphosphorylated tau species resistant to proteolysis 
[430], thus the combination of hyperphosphorylation and oxidative stress can be 
the main event leading to the accumulation of tau aggregates.  
NFTs are mainly composed by hyperphosphorylated tau but also mono and poly-
ubiquitinated tau forms, ubiquitin and subunits of the E3 ubiquitin ligase 
complex [59,431-434], suggesting a role of the UPS in tau degradation. The first 
evidence of an UPS involvement on tau degradation was obtained in vitro by 
showing that tau can be directly processed by the proteasome without 
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ubiquitination [435]. However, in tauopathies models conflicting results have 
been produced regarding the UPS role in tau turnover. For instance, in some 
mammalian cell lines tau was described as a proteasome substrate [412,435-437]. 
On the contrary, in other cancerous cell lines and in primary neurons where 
proteasome inhibition correlates with reduced tau protein levels as consequence 
of constitutive macro-autophagy activation tau is not a substrate [438-442]. 
Therefore, different forms of tau might follow different pathways in the same cell 
line, full-length tau is degraded by proteasome while truncated forms are targeted 
by autophagy [443]. Moreover, hyperphosphorylated and oligomeric forms of tau 
result in proteasome inhibition [430,444] that could lead to a positive feedback 
loop which might accelerate the disease progression.
Macro-autophagy and CMA are the other two routes involved in tau clearance 
that ends with its degradation within the lysosomes. In tauopathy models, a 
reduction of tau protein levels has been observed upon pharmacological 
activation of autophagy with rapamycin [442,445,446]. On the other hand, in 
CMA, tau proteolysis occurs via a selective lysosome internalization through the 
lysosomal receptor protein LAMP-2A assisted by the molecular chaperone 
Hsc70 [438]. Some mutant forms of tau seem to be responsible for autophagy 
impairment, since a dramatic accumulation of autophagosomes and lysosomes 
arises in tauopathy models expressing the P301L, G272V or R406W mutant tau, 
creating a self-accumulation loop [447-449].  
4.2.2. Tau and Cell-to-Cell Propagation 
In human brains of tauopathies, misfolded hyperphosphorylated tau first 
starts to accumulate in the locus coeruleus and then begins to spread to the 
entorhinal cortex and other brain regions in an age-associated process with a 
relatively uniform distribution [450] suggesting a cell-to-cell propagation. This 
theory was reconfirmed in animal models where human wild-type tau isoforms 
were injected into mice brains causing the pathology diffusion from the injection 
site to the neighbouring brain regions without neurodegeneration up to 18 
months. In the same animals, upon injection of the P301S mutant tau a massive 
neurodegeneration was observed after 5 months, suggesting that the toxic tau 
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species are different from the spreading ones [451,452]. Despite the absence 
of the secretion signal sequence, monomeric tau has also been detected in the 
brain interstitial fluid and in the media of cultured neurons causing 
neurotoxicity by enhancing the intracellular calcium concentration 
[453-456]. Moreover, in several models, insoluble tau aggregates were taken up 
via macro-pinocytosis inducing the aggregation of endogenous cytoplasmic tau. 
Tau aggregates are also directly released into the extracellular environment, 
however the secretion mechanism is still elusive [457-464]. 
4.3. Tau Physiopathology in Yeast Models 
S. cerevisiae does not possess any tau protein ortholog. Nevertheless, its 
genome is highly conserved and yeast cells have proven to be a versatile tool to 
study disease-related molecular processes such as protein misfolding in the field 
of neurodegenerative disorders [349,465] or to identify novel therapeutic 
compounds [466]. In yeast models cytotoxic repercussions upon overexpression 
of the human tau protein have never been reported. However, yeast has been used 
to study the impact of tau phosphorylation status and oxidative stress concerning 
the aggregation process. To do this, two particular yeast strains were used to 
assess the role of Mds1 and Pho85, the orthologous in yeast of mammalian 
GSK3B and CDK5 respectively, in tau phosphorylation, in combination with 
several different antibodies against specific phospho-epitopes with pathological 
significance. Deletion of MDS1 leads to decreased amount of phospho-tau 
detected by AD2 and PG5 antibodies. This was an expected observation as the 
AD2 epitope (S396/404) is a direct target of GSK3B [467]. Since the PG5 
epitope (S409) is a direct target of PKA, and not of GSK3B, it has been 
hypothesized that Mds1 might affect phosphorylation at this site indirectly 
[468]. On the other hand, deletion of PHO85 resulted in increased phospho-tau 
levels recognized by AD2 and PG5 antibodies (Figure 19) in correlation with 
augmented amount of tau in the sarkosyl insoluble fraction, index of 
enhanced aggregation rate dependent on tau phosphorylation status [469].  
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Figure 19: Tau immunoreactivity panel in W303-1A yeast cells. Phospho-tau 
immunoreactivity detected by AD2 and PG5 antibodies decreased in ΔMDS1 and increased in 
ΔPHO85 yeast strains [465]. 
In this yeast model, the deletion of MDS1 and PHO85 affects tau 
phosphorylation status in opposite ways as observed in vivo, whereas CDK5-
mediated inhibition of GSK3B occurs under particular conditions [419]. 
Furthermore, like proven in tauopathy mammalian models [412-414], an inverse 
relation between MT binding and tau phosphorylation status was demonstrated, 
as hyperphosphorylated tau isolated from ΔPHO85 strain shows a decreased MT 
binding affinity when compared with the ones isolated from the wild-type and 
ΔMDS1 yeast strains [470].
To deeply investigate the relation between tau phosphorylation and its 
aggregation, several FTDP-17 related tau mutants were expressed in different 
yeast strains. Notably, the P301L and R406W mutants showed a significant 
reduction in the phospho-epitope S409 detected by PG5 antibody, in 
correlation with a decreased aggregation propensity. To further confirm the 
influence of phosphorylated tau at S409 on its aggregation process the 
synthetic tau-S409A mutant was then used. This mutant showed a significant 
reduction in the sarkosyl insoluble fraction together with a decreased AD2 
(S396/404) immunoreactivity when compared with the wild-type (2N4R) tau 
(Figure 20) [471]. Therefore, tau phosphorylation at PG5 and AD2 epitopes 
seems to be interdependent and phosphorylation at S409 might prime 
the subsequent phosphorylation at S396/404. The same is observed in AD 
brains, where phosphorylation at S409 is an early event leading to the formation 
of NFTs, in which hyperphosphorylation at S396/404 is a pathological feature 
[472].  
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Figure 20: Tau immunoreactivity and aggregation rate. The S409A mutant tau shows 
decreased AD2 immunoreactivity and decreased aggregation ability by sarkosyl fractionation 
when compared with the wild-type tau (2N/4R), both in ΔPHO85 and wild-type yeast strains 
[465].  
As previously described, some evidence also exists between oxidative stress, 
mitochondrial dysfunction and tau pathology. In yeast, the role of oxidative stress 
on tau aggregation has been investigated in specific mitochondrial deletion 
mutants or by adding Fe2+, which is a known oxidative stress inducer. In both 
cases, it a significant increase of tau in the sarkosyl insoluble fraction was 
observed, through mechanisms that are independent of its phosphorylation status 
[471]. Taken together, these results recapitulate many important features 
implicated in tau pathology, including hyperphosphorylation and aggregation. 
Thus, the yeast model represents a useful tool to further clarify the fundamental 
cellular processes involved in tau biology and pathology. 
5. ASYN and Tau in Neurodegeneration
5.1. ASYN and Tau Interactions 
LB and NFTs are hallmarks of synucleinopathies and tauopathies, 
respectively. However, in patients’ brains co-localization of ASYN within NFTs, 
which are mainly composed of tau protein, and co-localization of tau within LB, 
which are mainly composed by ASYN protein, was observed, suggesting that a 
synergistic neurotoxic effect might exist [473-478]. The first evidence of 
interaction between ASYN and tau was proven in 1999 when a direct binding 
between the two proteins was revealed [324]. The ASYN binding domain in tau 
is localized to the MTBD region, while the tau binding site in ASYN resides in 
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the acidic C-terminal region, in analogy to the tau binding acidic C-terminal 
region of tubulin (Figure 21). In the same study a competition between ASYN 
and tubulin for the MTBD in tau was also demonstrated, whereas MT-bound tau 
was unable to interact with ASYN [324].  
Figure 21: Schematic representation of the ASYN and tau 2N4R binding sites. The tau 
MTBD containing region and the ASYN C-terminal region are the sites responsible for the direct 
binding between these two proteins. 
The direct binding between these two proteins is abolished by the tau P301L 
mutation associated with frontotemporal dementia, while the ASYN affinity to 
tau is decreased by the ASYN A30P disease-related mutation [479,480]. The self 
oligomerization of ASYN and tau gives rise to the formation of LB and NFTs 
respectively. In vitro assays showed how co-incubation of tau 2N4R and wild-
type ASYN promotes the polymerization of both proteins in a time-dependent 
manner [250]. Similar results have also been reported in mammalian and animal 
models. In cells overexpressing the human tau 2N4R, recombinant prefibrillized 
ASYN seeds promote the formation of large round shaped intracellular 
aggregates, with LB-type morphology, composed of both ASYN and tau proteins 
[481]. Additionally, double transgenic mice co-expressing wild-type ASYN and 
P301L mutant tau show ASYN positive and tau positive inclusions in 
oligodendrocytes that are not observed when wild-type ASYN or tau P301L are 
solely expressed [250]. Since oligodendrocytes express very low levels of 
endogenous ASYN and tau proteins, the formation of amyloidogenic Thioflavin-
S positive pathological inclusions is due to the interaction of transgenic ASYN 
and tau proteins that facilitate and promote each other's fibrillization [250,481]. 
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Besides the ability of these two proteins to promote the fibrillization of each 
other, a synergistic cytotoxic effect upon co-expression of ASYN and tau has 
also been reported. In mammalian models of synucleinopathy, co-expression of 
tau enhances ASYN aggregation and toxicity increasing the number of ASYN 
inclusions per cell and reducing their size [482]. Likewise, in yeast, a synergistic 
cytotoxicity has been observed in cells that combine the expression of wild-type 
tau and wild-type ASYN or P301L mutant tau either with wild-type or A53T 
mutant ASYN [347].  
Tau phosphorylation status plays an important role in the etiology of all 
tauopathies. NFTs are characterized by the presence of hyperphosphorylated tau 
species and in many studies an ASYN-mediated effect on tau phosphorylation 
has been reported. ASYN is able to induce tau phosphorylation through indirect 
mechanisms increasing the activity of several kinases which are directly involved 
in the tau phosphorylation cascade. In detail, ASYN protein is able to enhance 
the activity of GSK3B, PKA and c-jun kinases (JNK) increasing the tau 
phosphorylation status and thus reducing its binding affinity for the MT, 
facilitating the formation of potential cytotoxic oligomeric species [324,481,483- 
485]. Moreover, there is an increasing evidence that genetic susceptibility 
contributes to the etiology of PD. Recently, GWAS confirmed that SNCA and 
MAPT (H1 haplotype) genes are two of the main common contributors to 
idiopathic PD [486-488]. Taken together, all these results reveal that the 
interaction between ASYN and tau (Figure 22) may be a relevant disease 
component that enhances the pathological cascade and spreads the neuronal 
damage in synucleinopathies and tauopathies. However, the molecular pathways 
by which these synergistic effect leads to neurodegeneration are still unclear. The 
development of new experimental models to shed light into the mechanisms 
involved in this synergistic toxicity mediated by ASYN and tau proteins will be 
useful to further understand the physiopathology of these devastating illnesses. 
42
Figure 22: Schematic representation of ASYN and tau interactions. A) ASYN enhances the 
activity of different kinases involved in tau phosphorylation [324,481,483-485]. B) Co-expression 
of ASYN and tau leads to the formation of intracellular inclusions immunoreactive for both 
proteins [250,481]. C) In synucleinopathy models tau enhances ASYN-mediated cytotoxicity 
[347,482]. 
5.2. A Dual Target for Therapeutic Intervention 
Synucleinopathies and tauopathies regroup a wide number of 
neurodegenerative diseases that share common molecular mechanisms. In these 
disorders the presence of intracellular protein aggregates is a dominant feature 
and, in some cases, both ASYN and tau co-localize in the same inclusion. During 
the last century the role of ASYN and tau in the pathology progression has been 
largely investigated and many molecular pathways leading to neurodegeneration 
have been identified. The common mechanisms by which ASYN and tau induce 
neurodegeneration and cell death are related to self oligomerization leading to the 
formation of potential cytotoxic oligomeric species, calcium dependent cell 
signalling, mitochondrial activity, cytoskeleton assembly, protein quality control 
system, cell-to-cell propagation and immune response activation. More recently, 
many direct and indirect interactions between ASYN and tau and a synergistic 
cytotoxic effect have also been revealed. Given all these analogies in the 
physiopathology of synucleinopathies and tauopathies and the cytotoxic synergy 
of ASYN and tau, these two proteins might represent a dual target to develop 
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novel therapeutic approaches to treat a wide number of neurodegenerative 
disorders. 
6. Goal of the Project: Identification of Modulators of
ASYN and Tau Interaction 
Starting around 1960, S. cerevisiae was introduced as an experimental 
system for molecular biology [489] and in 1996 yeast was the first eukaryotic 
organism for which the complete genomic sequence could be established 
[490,491]. Most importantly, about 30% of human genes involved in 
the development of many human diseases have functional orthologous in yeast 
[492]. Yeast are used for the high-throughput screening (HTS) of libraries 
due to advantages such as evaluation of compounds in a physiologically 
relevant environment and immediate negative selection of toxic compounds or 
those with poor membrane permeability [493]. Moreover, collections of 
deletion mutant strains are available together with overexpression 
collections [494-497], providing powerful tools for genome-wide screening 
(GWS) assays. Despite the absence of a nervous system, yeast cells have been 
largely used to get insight into neurodegenerative disorders [349,465,498,499], 
as many of the pathways involved in pathology progression, such as 
mitochondrial activity, transcriptional regulation, intracellular trafficking and 
protein quality control, are well conserved among yeast and human [500]. 
In yeast models, ASYN expression has been widely described as causing 
toxicity and growth delay, whereas expression of tau has no apparent 
consequence on cell growth [354,364,470,471]. Co-expression of ASYN and 
tau was previously promoted in yeast and was reported to be synergistically 
toxic, although ASYN expression alone resulted in no phenotype [347]. 
However, a detailed characterization to shed light into the molecular 
pathways involved in this synergistic cytotoxicity is still missing.  Our goal is to 
create a new yeast model to investigate the synergistic cytotoxic effect 
mediated by the co-expression and interaction of ASYN and tau proteins. The 
model will be characterized to identify the molecular mechanism by which the 
interaction between ASYN and tau is responsible for enhanced cytotoxicity. 
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After having a powerful model, representative of the toxic synergistic effect 
between ASYN and tau, we will perform GWS and HTS assays to identify genes 
and compounds able to modulate the synergistic toxic phenotype caused by the 
concomitant expression of ASYN and tau. The identification of the target genes 
and compounds in yeast, represent a valid preliminary screening to shed light in 
the molecular pathways involved in neurodegeneration leading to cell death. 
Thus, the identified modulators might be a plausible starting point for further 
investigations in mammalian models with increased physiological relevance.  
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Chapter II. Results 
1. A Powerful Yeast Model to Investigate the Synergistic
Interaction of ASYN and Tau in Neurodegeneration 
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Abstract
Several studies revealed consistent overlap between synucleinopathies and tauopathies, demonstrating that a-synuclein
(ASYN) and tau co-localize in neurofibrillary tangles and in Lewy bodies from Alzheimer’s and Parkinson’s disease patients
and corresponding animal models. Additionally, it has been shown that ASYN can act as an initiator of tau aggregation and
phosphorylation and that these two proteins directly interact. Despite these evidences, the cellular pathway implicated in
this synergistic interaction remains to be clarified. The aim of this study was to create a yeast model where the concomitant
expression of ASYN and tau can be used to perform genome wide screenings for the identification of genes that modulate
this interaction, in order to shed light into the pathological mechanism of cell dysfunction and to provide new targets for
future therapeutic intervention. We started by validating the synergistic toxicity of tau and ASYN co-expression in yeast, by
developing episomal and integrative strains expressing WT and mutant forms of both proteins, alone or in combination. The
episomal strains showed no differences in growth delay upon expression of ASYN isoforms (WT or A53T) alone or in
combination with tau 2N/4R isoforms (WT or P301L). However, in these strains, the presence of ASYN led to increased tau
insolubility and correlated with increased tau phosphorylation in S396/404, which is mainly mediated by RIM11, the human
homolog of GSK3b in yeast. On the other hand, the integrative strains showed a strong synergistic toxic effect upon co-
expression of ASYN WT and tau WT, which was related to high levels of intracellular ASYN inclusions and increased tau
phosphorylation and aggregation. Taken together, the strains described in the present study are able to mimic relevant
pathogenic features involved in neurodegeneration and are powerful tools to identify potential target genes able to
modulate the synergistic pathway driven by ASYN and tau interaction.
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Introduction
In the last decade, several studies, from genetic features to direct
interaction, have revealed a consistent overlapping between
synucleinopathies and tauopathies [1–3]. Synucleinopathies con-
sists of a group of disorders in which the pathological hallmark is
the presence of insoluble fibrillary aggregates of alpha-synuclein
(ASYN) protein, designated by Lewy bodies, in specific brain cells
populations. The disorders included in this group are Parkinson’s
disease (PD), dementia with Lewy bodies (DLB) and multiple
system atrophy (MSA) [4,5]. The first two mentioned diseases are
characterized by the presence of Lewy bodies in the dopaminergic
neurons in the substantia nigra of the mid brain region and in the
cholinergic neurons in the brainstem, limbic and cortical region,
whereas in MSA glial cells are affected showing a high density glial
cytoplasmatic inclusions (GCIs) ASYN-positives [4,5]. In most
cases PD is a idiopathic disease, involving polygenic mutations,
gene interactions and lifestyle, whereas monogenic forms are very
rare with only around 20% of cases reporting hereditary features
[6–9]. ASYN gene (SNCA) was the first gene discovered to be
associated with PD. It was observed that duplication or triplication
[10,11] of the SNCA gene, along with three missense mutations
(A30P, E46K and A53T), are all related to familial PD [12–14].
Tauopathies represent another group of neurodegenerative
disorders also characterized by the aberrant aggregation of
specific proteins. The pathological hallmark of tauopathies
consists in the presence of neurofibrillary tangles (NFT) labelling
positive for tau protein [15,16]. The accumulation of these
tangles leads to progressive brain atrophy due to frontotemporal
or striatonigral degeneration. Pathologies such as Alzheimer’s
disease (AD), frontotemporal lobar degeneration (FLD), progres-
sive supranuclear palsy (PSP) and corticobasal degeneration
(CBD) are all examples of tauopathies [17]. How NFTs are
formed in these diseases is still under investigation. It is known
that the paired helical filaments (PHF) of NFT are constituted
by hyperphosphorylated tau, mainly promoted by the kinase
GSK3b which was shown to phosphorylate tau in up to 30
distinct sites [18–20]. In addition to hyperphosphorylation, there
are also some tauopathies such as frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17) in which
tau’s missense mutation P301L is known as an ‘‘aggregation-
prone mutation’’ [21,22].
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The overlapping between synucleinopathies and tauopathies
involves many aspects. Genome-wide association studies have
shown that the microtubule-associated protein tau (MAPT)
haplotype H1 displays a significant association with PD [3,23].
Other studies showed ASYN being localized in NFTs, which
are mainly composed by tau, and tau localized in Lewy bodies,
mainly composed by ASYN [2,24–26]. In fact, in a double
transgenic mice expressing human ASYN WT in combination
with human P301L mutant tau, these two proteins have been
shown to co-localize in the same intracellular inclusions [27]. A
direct binding between these two proteins has also been
described with disease-related mutations being shown to
interfere with this interaction [1,28]. Moreover, it was also
described that ASYN can act as a pathological initiator of tau
phosphorylation and aggregation, both in vitro and in vivo [29–
32]. Whereas reduction of endogenous tau levels in murine
models of Alzheimer’s disease has been shown to improve
cognitive performance [33–35], tau reduction did not prevent
motor deficits in mouse models of PD [36]. These observations
rely on the use of two specific animal models and cannot be
extrapolated for other models or to the human PD condition
without further validation. In addition, implication of tau levels
in cognitive function cannot be ruled out. Interestingly, neurite
degeneration has been directly correlated with tau protein levels
and phosphorylation state in a Drosophila model of PD [37].
Therefore, the mechanism by which ASYN and tau synergis-
tically interact and its role in pathology deserves further
investigation.
Yeast models are validated tools for the study of neurodegen-
erative diseases [38,39]. In fact, both cellular mechanism of action
and phenotypical repercussions derived from ASYN expression
have been largely studied in yeast [40,41], a non-expensive, easy to
handle and with a short replication time model. Whereas ASYN
expression in yeast has been widely described as causing toxicity
and growth delay, expression of tau in yeast has no apparent
consequence on cell growth [42,43]. Neither ASYN nor tau have
orthologues in yeast, thus allowing the development of unbiased
models of human transgene expression, with no interference or
competition from endogenous yeast proteins. Co-expression of
ASYN and tau was previously promoted in yeast and was reported
to be synergistically toxic, although ASYN expression alone
resulted in no phenotype [44]. We wanted to further explore this
synergistic phenotype, by making use of distinct expression
systems, where protein levels and transgene copy numbers can
be more stably maintained. Our goal was to develop a yeast model
of ASYN and tau co-expression that will be used for the
identification of genes able to modulate this synergistic interaction
and hence relevant as future therapeutic targets for human
neurodegenerative diseases. Therefore, in the current work, we
report the development of different wild type (WT) yeast strains,
BY4741 and W303-1A, co-expressing ASYN and tau from
episomal or integrative vectors, with the aim of identifying a toxic
phenotype caused by the synergistic interaction between the two
proteins. Both episomal and integrative strains were further
characterized by analyzing the formation of ASYN intracellular
inclusions and tau aggregation and phosphorylation states. This
detailed characterization allowed the identification of a synergistic
toxic effect probably triggered by the presence of ASYN WT
cytoplasmatic inclusions and insoluble phosphorylated tau WT.
The yeast strains developed in this work are being used as tools for
the identification of potential target genes able to modulate the
synergistic interaction observed between ASYN and tau in
neurodegenerative diseases.
Materials and Methods
Yeast Strains and Media
The following Saccharomyces cerevisiae strains were used in this
study: BY4741 (MATa his3D1 leu2D0 met15D0 ura3D0), W303-1A
(MATa leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15) (T.
Outeiro IMM) and the single deletion mutant DRIM11 was
obtained from the genome-wide yeast deletion collection
YSC1053 (Open Biosystems) [45]. All strains were grown in
synthetic complete media (SC) which consists of 0.67% yeast
nitrogen base (Sigma-Aldrich), 0.067% yeast drop-out mix (MP
Bio) and 2% (w/v) carbon source glucose, galactose or raffinose,
(Sigma-Aldrich) depending on the experiments, solid media plates
also contain 2% agar (BD).
Plasmids
Tau (2N/4R) WT and P301L variants were subcloned from
YIpLac128 Gal1 (BIOALVO) into pESC-LEU, a bidirectional
high-copy (2m) episomal vector (Stratagene), under Gal1 promoter
using the restriction sites ApaI N-terminal and XhoI C-terminal.
ASYN WT and A53T variants were subcloned from pRS426
GPD (T. Outeiro IMM) into the same pESC-LEU vector but
under Gal10 promoter using the restriction sites SpeI N-terminal
and HindIII/SacI blunt end C-terminal and into pRS306 Gal1
(BIOALVO) using the restriction sites SpeI N-terminal and
HindIII C-terminal. BY4741 WT and DRIM11 yeast strains were
transformed with the episomal vector pESC-LEU harbouring
ASYN (WT or A53T) and tau (WT or P301L) alone or in
combination. W303-1A yeast strain was transformed with the
integrative vectors pRS306 Gal1 harbouring ASYN (WT or
A53T) and YIpLac128 Gal1 harbouring tau (WT or P301L) alone
or in combination. Both transformation of yeast strains using the
lithium acetate method and transformants colony selection were
performed as described in [46]. Confirmation of integration was
performed by PCR using the following primers: fw_aggagcaca-
gacttagattg and rw_ttggagcctacatagagaac for the pRS306 Gal1
harbouring ASYN isoforms and fw_gcaatcgtcttactttctaa and rw_
gcaaatagtctacaaaccag for the YIpLac128 Gal1 harbouring tau
isoforms.
Spotting Assays and Growth Curves
Cell growth was analysed on solid selective SC medium to
maintain selection for plasmids by spot assay by performing 5x-
fold serial dilutions of exponential growing cultures, starting at
OD600 = 1,0. For this, cells were pre-grown overnight at 30uC with
agitation (200 rpm) in selective SC medium, containing raffinose.
After this pre-incubation, cells were re-inoculated in the same
selective SC medium at OD600 of 0,2 and left to grow at 30uC with
agitation (200 rpm) until an OD600 of 1.0 was reached. Spot plates
containing glucose (non-inducing medium) or galactose (inducing
medium) were incubated at 30uC or 37uC with images being
acquired after 72 h of incubation. Quantification analysis was
performed using ImageJ [47] acquiring the intensity of all the spots
in each lane from the plates containing galactose and then
normalized versus the respective values obtained from the control
plate containing glucose. Statistical significance was determined by
performing one-way ANOVA with post-hoc Dunnett’s test using
GraphPad Prism. Growth was also analysed in liquid medium. For
this, cells were pre-grown overnight at 30uC with agitation
(200 rpm) in selective SC medium containing raffinose. After this
pre-incubation, cells were re-inoculated in selective SC medium
containing glucose (non-inducing medium) or galactose (inducing
medium) and incubated at 30uC or 37uC in 96 well plates. Growth
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was automatically monitorized by measuring OD600 using a
PerkinElmer Victor 3V spectrophotometer.
Immunoblotting
Immunoblotting was conducted following standard procedures
[48] with some minor modifications. Yeast cells were pre-grown at
30uC with agitation (200 rpm) in selective SC medium containing
raffinose. After this pre-incubation, cells were inoculated at OD600
of 0,2 in selective SC medium containing galactose and incubated
overnight at 30uC (W303-1A) or 37uC (BY4741 WT and
DRIM11) with agitation (200 rpm). Cells were harvested by
centrifugation, washed in sterile water and pellets were resus-
pended in 100 ml of 1X SDS sample buffer (60 mM Tris-HCl
pH 6.8, 10% glycerol, 2% SDS, 70 mM bME, 1% bromophenol
blue supplemented with 1x protease inhibitor cocktail (Sigma-
Aldrich) and 1x PhosSTOP (Roche) phosphatase inhibitor
cocktail). After resuspension, pellets were lyzed by boiling for 5
minutes. 15 ml of each sample was run in a 12% SDS-PAGE gel
and blotted onto PVDF membrane. Immunodetection was carried
out using the following primary antibodies: Total tau (Polyclonal
Rabbit anti-Human Tau, Dako) diluted 1:10000, phospho tau in
S396/404 (Mouse AD2 Anti-Tau Protein mAb, BioRad) diluted
1:5000, ASYN (Purified Mouse Anti-a-Synuclein, BD) diluted
1:1000 and GAPDH (Mouse Monoclonal Anti-GAPDH, Ambion)
diluted 1:3000, all in in TBST containing 1% milk. The following
secondary antibodies were used: Goat Anti-Mouse IgG (H+L)-
HRP Conjugate (BioRad) diluted 1:10000 and oat Anti-Rabbit
IgG (H+L), Horseradish Peroxidase conjugate (Invitrogen) diluted
1:10000, all in TBST containing 1% milk. Membranes were
revealed using Immobilon Western Chemiluminescent HRP
Substrate (Millipore) and digital images acquired with Alliance
4.7 (UVITECH Cambridge). Quantification analysis was per-
formed using ImageJ [47] and statistical significance was
determined by performing one-way ANOVA with post-hoc
Dunnett’s test using GraphPad Prism.
Sarkosyl Fractionation
Sarkosyl fractionation method was performed as described in
[49] with some minor modifications. Yeast cells were pre-grown
overnight at 30uC with agitation (200 rpm) in selective SC
medium containing raffinose. After this pre-incubation, cells were
re-inoculated at OD600 = 0,2 in 50 ml of selective SC medium
containing galactose and incubated for 24 hours at 30uC (for
W303-1A) or 37uC (for BY4741 WT) with agitation (200 rpm).
Cells were then harvested by centrifugation, washed in sterile
water and pellets were resuspended in 500 ml of Extraction Buffer
(100 mM Tris-HCl pH 7,9, 250 mM ammonium sulfate, 1 mM
EDTA, 10% glycerol, 0,5 mM DTT supplemented with 1x
protease inhibitor cocktail (Sigma-Aldrich)). Resuspended cells
were homogenized with glass beads for 10 minutes at 4uC, total
protein extract concentration was measured by Bradford protein
measurement method assay [50] and adjusted to 1 mg/ml (Input).
Sarkosyl (Sigma-Aldrich) was added to the lysates to a final
concentration of 1% and samples were incubated at room
temperature for 5 minutes. Sarkosyl-soluble and insoluble fractions
were separated by centrifugation at 35,000 g for 1 h at 4uC. Pellets
were washed once with extraction buffer and centrifuged at
35,000 g for 30 min to eliminate residual protein from soluble
fractions. After centrifugation, pellets were resuspended in 15 ml of
1X SDS sample buffer and boiled for 5 min, before loading onto a
12% SDS-PAGE gel. Equal volumes of input and sarkosyl soluble
fraction were diluted with 2X SDS sample buffer and boiled for
5 min, before loading onto 12% SDS-PAGE gel.
Immunofluorescence
Immunofluorescence was performed as described in [51] with
some minor modifications. Yeast cells were pre-grown at 30uC
with agitation (200 rpm) in selective SC medium containing
raffinose. After this pre-incubation, cells were re-inoculated at
OD600 = 0,2 in 4 ml of selective SC medium containing galactose
and incubated overnight at 30uC (W303-1A) or 37uC (BY4741
WT) with agitation (200 rpm). Cells were then fixed in 4%
formaldehyde for 1 hour at 30uC. Cells were then harvested by
centrifugation, washed in sterile water, treated to form sphero-
plasts, (1 hour at 30u in K2HPO4 50 mM, KH2PO4 50 mM,
MgCl2 0,5 mM, sorbitol 1,2 M, bME 70 mM, Lyticase 50 mg/ml,
pH 6,8), washed in PBS and fixed onto poly-lysine-coated slides.
Permeabilization was then performed with PBS containing 0,2%
Triton-X100 for 15 minutes, after which cells were washed two
times with PBS and subsequently blocked with PBS containing
0,5% BSA for 10 minutes. Fixed cells were then incubated with
anti-ASYN primary antibody (ASYN Purified Mouse Anti-a-
Synuclein, BD) diluted 1:100 in PBS containing 0,1% BSA for 1
hour, washed and incubated with CY3 conjugated secondary
antibody (Cy3H Goat Anti-Mouse IgG (H+L) Invitrogen) diluted
1:500 in PBS containing 0,1% BSA for 30 minutes. After antibody
labelling samples were mounted in a glycerol mounting media
containing DAPI (1 mg/ml in 90% glycerol) and analysed using a
Zeiss AxioObserver.D1 microscope. Image acquisition was per-
formed with the software AxioVision (Zeiss). Statistical significance
was determined by performing one-way ANOVA with post-hoc
Dunnett’s test using GraphPad Prism.
Results
Cytotoxic Growth Effects Upon High-copy Plasmid
Expression of ASYN Alone or in Combination with Tau
We started promoting the co-expression of ASYN and tau 2N/
4R isoforms in yeast by transforming the WT strain BY4741 with
a bi-directional inducible high-copy plasmid containing ASYN
(WT or A53T) and tau (WT or P301L) coding sequences alone or
in combination. By using a bi-directional vector, our goal was to
achieve a more controlled expression of both transgenes, as the use
of two independent episomal plasmids results in copy number
variation and, subsequently, in different and variable levels of
protein expression. As observed by western blot, all the
transformants showed equal protein expression levels of ASYN
isoforms, while expression of tau isoforms strongly decreased when
expressed in combination with ASYN (WT or A53T) (Fig. 1,A).
This decrease is not a specific effect to ASYN, as co-expression of
tau isoforms with a control protein led to the same alterations in
tau total protein levels (data not shown). The growth profile upon
expression of ASYN and tau variants alone and in combination
was evaluated in both solid and liquid media. Dot spot analysis
revealed that expression of ASYN (WT or A53T) at 37uC causes
growth delay, as reported in previous studies [40]. In contrast,
expression of tau (WT or P301L) had no effect on yeast fitness
which has also been observed previously [38]. Yeast strains co-
expressing ASYN isoforms and tau showed a similar growth delay
as observed upon expression of ASYN alone, with no evident
synergistic effect being detected. In contrast to the cytotoxic
growth effect observed for ASYN (WT or A53T) expressed alone
or in combination with tau (WT or P301L) in solid media, no
growth delay was observed in liquid media (Fig. 1,C). These data
strongly suggest that the cytotoxic growth effect phenotype
observed in these episomal strains is mainly mediated by the
expression of ASYN isoforms. Nevertheless, tau levels were
Yeast Models of a-Synuclein and Tau
PLOS ONE | www.plosone.org 3 February 2013 | Volume 8 | Issue 2 | e55848
49
Yeast Models of a-Synuclein and Tau
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e55848
50
reduced upon co-expression, which might have hindered the
observation of a synergistic phenotype.
ASYN Increases Tau Insoluble Aggregation State
It is demonstrated that in mammalian cellular models tau co-
localizes with ASYN aggregates with overexpression of tau leading
to an increase in the number of ASYN inclusions and to a
reduction in their size [31,52]. To further characterize and to
assess if similar effects are present in the episomal yeast strains
generated, the percentage of cells showing ASYN intracellular
inclusions was quantified by immunofluorescence. No differences
were observed, in terms of size and number of ASYN intracellular
inclusions between the strains expressing ASYN isoforms alone or
in combination with tau isoforms (Fig. 2,A). Interestingly, in the
double mutant ASYN A53T/tau P301L, cells with large
aggregates were not detected (Fig. 2,A). In order to quantify tau
intracellular inclusions, anti-tau immunofluorescence was also
tried using different antibodies but no specific signal was ever
detected. As an alternative, sarkosyl fractionation was applied as
this technique is largely used to characterize the solubility of
intracellular protein aggregates in the brain of PD or AD patients
[53,54] as well as in animal and cellular models of neurodegen-
eration [43,55,56]. Results obtained showed that all ASYN and
tau isoforms, expressed alone or in combination, are present in the
sarkosyl insoluble fraction (Fig. 2,B). ASYN isoforms alone or in
combination appear to be evenly distributed between the soluble
and insoluble fractions. Tau WT seems to be slightly more
concentrated in the insoluble fraction whereas tau P301L looks to
be marginally more abundant in the soluble fraction (although this
might be due to small differences in total protein loading, as
GAPDH intensity also seems to be higher for this sample).
Interestingly, co-expression of tau isoforms with ASYN leads to an
increase in the proportion of insoluble tau (Fig. 2,B), as observed
by the higher amount of tau present in the sarkosyl insoluble
fraction when compared to the soluble fraction. Therefore,
whereas tau expression, at least up to this protein level, does not
seem to affect ASYN intracellular inclusion number and size,
ASYN expression increases the insoluble fraction of tau.
ASYN Increases Tau Phosphorylation in S396/404 via
RIM11
Hyperphosphorylated tau is the main component of PHF of
NFT in the brain of AD patients [57,58]. As we observed that the
presence of ASYN leads to an increase in tau insoluble aggregation
state (Fig. 2,B) we next evaluated the phosphorylation status of tau
in the episomal yeast strain co-expressing ASYN and tau. To
assess tau phosphorylation level, western blot analysis was
performed using AD2 antibody, which recognizes phosphorylated
tau at S396/404. This form of tau is crucial for tau fibrillization
and [18,19] is characteristic of PHF in Alzheimer’s disease [59].
Analysis of AD2 immunoreactivity versus total tau showed that tau
WT and tau P301L are phosphorylated to the same extend when
expressed alone (Fig. 3,A) but display a significant increase in
S396/404 phosphorylation in the presence of ASYN. The
increased relative level of phosphorylation of tau isoforms is even
more striking upon co-expression with ASYN A53T (Fig. 3,A).
S306/404 of tau is a typical GSK3b substrate [20,42]. In order
to evaluate if the increased tau phosphorylation observed upon co-
expression of ASYN was mediated by GSK3b, we used a yeast
strain lacking the orthologue of human GSK3b. Yeast cells carry
four orthologues of human GSK3b and it is already known that
RIM11 can act as a tau kinase and that the AD2 phosphoepitope is
significantly reduced or absent in these mutant strains [42,60].
Hence, the inducible high-copy plasmid expressing ASYN (WT or
A53T) and tau (WT or P301L), alone or in combination, was
transformed in a DRIM11 mutant yeast strain, in order to evaluate
tau phosphorylation state in the presence and absence of ASYN.
Results showed that the AD2 tau phosphoepitope was not detected
in any of the samples tested, corroborating that the increased tau
phosphorylation in S306/404 observed in the presence of ASYN is
fully mediated by RIM11. Growth ability test in solid media
showed that lacking of tau phosphorylation in S396/404 does not
alter the growth phenotype observed in BY4741 WT yeast strain
(Fig. 3,C). This was an expected outcome, as expression of tau
seems to be non-related to the growth arrest effect observed.
Taken together, the finding that tau phosphorylation in S396/404
via RIM11 is increased in the presence of ASYN is in accordance
with what has been described in other models, where it was
demonstrated that in vitro ASYN directly stimulates tau phosphor-
ylation via GSK3b [61], while in vivo and in post-mortem brain
from PD high levels of active GSK3b and hyperphosphorylated tau
were observed [62,63]. Our yeast strain thus mimics relevant
pathological features of neurodegeneration diseases where inter-
action between ASYN and tau occurs. Nevertheless, increased
cytotoxicity due to tau hyperphosphorylation was not observed.
This might be due to the lower tau intracellular levels upon co-
expression with ASYN. A model where tau protein levels were
higher would facilitate the assessment of pathological synergistic
interactions with ASYN.
Strong Synergistic Growth Effect Upon Genome
Integration of ASYN WT and Tau WT
We next accessed the synergistic phenotype of ASYN and tau
expression using an integrative yeast model by inserting one
copy of ASYN (WT or A53T) and tau (WT or P301L), alone or
in combination, into the genome of W303-1A yeast strain. Our
goal was to use a more stable and independent system for the
expression of the two transgenes, in order to achieve higher
intracellular tau levels. Integration was performed using specific
yeast vectors able to recombine with the yeast genomic DNA at
defined sites and correct integration was confirmed by PCR.
After generation of the integrative strains, ASYN and tau
protein expression level and tau phosphorylation in S396/404
were evaluated by western blot. As desired, tau (WT and
P301L) expression levels, alone and in combination with ASYN,
were significantly higher and constant among all strains
(Fig. 4,A). ASYN protein levels were generally constant, with
Figure 1. Cytotoxic growth effects upon high-copy plasmid expression of ASYN alone or in combination with Tau. A) High expression
level of ASYN (WT and A53T) and tau (WT and P301L), detectable by western blot upon expression with pESC-LEU bidirectional high-copy (2m)
episomal vector. Whereas ASYN levels (WT and A53T) are similar when either expressed alone or in combination with tau (WT or P301L), tau (WT and
P301L) levels are strongly decreased when expressed in combination with ASYN (WT or A53T), (***p,0,001). GAPDH was used as loading control. B)
Strong growth delay observed by dot spot at 37uC after 72 hours of incubation upon expression of ASYN (WT and A53T) alone or in combination with
tau (WT and P301L). Expression of tau (WT or P301L) alone has no effect on cells vitality whereas when expressed in combination with ASYN (WT and
A53T) cytotoxicity is observed. A quantitative plot of the dot spots is shown. Results are representative of at least three independent experiments. C)
No differences observed upon expression of ASYN and tau isoforms alone or in combination by growth ability tests performed in liquid media using
96 well plates at both 30uC and 37uC. All results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0055848.g001
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the exception of strains co-expressing tau P301L, which
displayed reduced expression of ASYN, for both WT and
A53T isoforms (Fig. 4,A). The observed differences in ASYN
protein levels can not be interpreted as a specific consequence
of tau co-expression, as they might merely reflect clonal
variation among strains. Interpretation of these differences
needs further experimental clarification. Quantification of tau
phosphorylation levels revealed that the presence of ASYN did
not induce significant changes, most probably due to the lower
levels of intracellular ASYN (or, at least, to the lower ratio of
ASYN/tau) (Fig. 4,A). Exception to this was the strain co-
expressing tau WT and ASYN WT, which displayed a huge
increase in the relative fraction of phosphorylated tau.
Cytotoxic growth effects were also assessed in this integrative
model in both solid and liquid media. As expected, dot spot results
showed that expression of ASYN WT and A53T at 30uC caused
moderate and high cytotoxic growth phenotypes, respectively
(Fig. 4,B). Despite the high expression level of tau isoforms in this
integrative model, tau expression alone didn’t show any effect in
yeast growth in either solid or liquid media (Fig. 4,B and C). A
strong synergistic growth effect was observed upon co-expression
of ASYN WT and tau WT (Fig.4,B), which was even more
pronounced at 37uC (Fig. 4,B). A similar growth delay was also
obtained in liquid media showing the robustness of the alterations
observed (Fig. 4,C). The synergistic growth effect observed for this
integrative strain seems to be correlated with the increased tau
phosphorylation state.
We observed an apparent rescue of toxic phenotype upon co-
expression of ASYN (WT and A53T) with tau P301L, as the
corresponding strains display increased growth fitness (Fig. 4, B).
Nevertheless, expression levels of ASYN WT and ASYN A53T in
both these strains is significantly lower (Fig. 4, A), and thus the
improved growth might be merely a consequence of a less toxic
intracellular environment due to less ASYN and not a true rescue
by P301L.
Figure 2. ASYN increases Tau insoluble aggregation state. A) Immunofluorescence with an anti-ASYN antibody showed no significant
differences between the percentage of cells that contain ASYN (WT and A53T) intracellular inclusions when expressed alone or in combination with
tau (WT and P301L). No yeast cells with ASYN big inclusions were observed in the strain expressing ASYN A53T in combination with tau P301L For
statistical analysis at least 800 cells were counted. B) Both ASYN (WT and A53T) and tau (WT and P301L) form intracellular sarkosyl insoluble
aggregates when expressed either alone or in combination, which are detectable by western blot. GAPDH was used as loading and soluble protein
control. *corresponds to an unspecific band. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0055848.g002
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Figure 3. ASYN increases Tau phosphorylation in S396/404 via RIM11. A) Relative percentage of phosphorylated tau (WT and P301L) in S396/
404 labelled by the antibody AD2 was increased in the presence of ASYN (WT and A53T). (*p,0,05; **p,0,01). GAPDH was used as loading control. B)
No phosphorylated tau (WT or P301L) detected in DRIM11 mutant by western blot when expressed alone or in combination with ASYN (WT or A53T).
GAPDH was used as loading control. C) Lack of tau (WT and P301L) phosphorylation in S396/404 doesn’t alter cytotoxicity observed in solid media
when tau (WT or P301L) and ASYN (WT and A53T) are expressed alone or in combination in DRIM11 as compared to expression in BY4741 WT.A
quantitative plot of the dot spots is shown (*p,0,05; **p,0,01; ***p,0,001). Results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0055848.g003
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Figure 4. Strong synergistic growth effect upon genome integration of ASYN WT and Tau WT. A) ASYN protein expression levels
detectable by western blot, remain generally constant, displaying a reduction upon co-expression of either tau isoform. Total tau expression levels
remain constant whereas the percentage of tau WT phosphorylated in S396/404 increases only in the presence of ASYN WT. (*p,0,05; **p,0,01).
GAPDH was used as loading control. B) Slight growth delay observed by dot spot at 30uC upon expression of ASYN WT, high growth delay with ASYN
A53T and strong synergistic cytotoxicity observed when ASYN WT and tau WT are co-expressed. At 37uC a total growth arrest is observed for the
Yeast Models of a-Synuclein and Tau
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High Percentage of ASYN Cytoplasmatic Inclusions and
Insoluble Tau Correlate with the Synergistic Growth
Effect
To further investigate the synergistic interaction detected
between ASYN and tau in the integrative yeast strains developed
in this work, we accessed the aggregation state of ASYN and tau
by immunofluorescence and sarkosyl fractionation experiments.
Interestingly, the number of ASYN intracellular inclusions
detected by immunofluorescence didn’t remain constant in all
strains. Strains expressing ASYN alone or ASYN WT in
combination with tau WT displayed a high level of cells with
ASYN inclusions. A reduction in the number of cells with
inclusions was observed in the strain expressing ASYN WT in
combination with tau P301L and in both the strains expressing
ASYN A53T in combination with tau (WT or P301L) (Fig. 5,A).
Furthermore, changes in ASYN intracellular inclusion localization
were also observed. It is known that in yeast ASYN initially
localizes to the membrane, and subsequently starts to form small
membrane localized inclusions that finally convert into larger
cytoplasmatic inclusions [44]. The majority of yeast cells
expressing ASYN isoforms alone and ASYN WT in combination
with tau WT showed only the most advanced cytoplasmatic
inclusions. On the other hand, the strain co-expressing ASYN WT
and tau P301L showed only small membrane connected
inclusions, whereas in the strains co-expressing ASYN A53T and
tau isoforms both membrane connected and cytoplasmatic
inclusions were observed (Fig. 5,B). Sarkosyl fractionation assays
showed ASYN equally distributed between the sarkosyl soluble
and insoluble fractions in all the strains expressing ASYN isoforms
alone or in combination with tau isoforms, whereas insoluble tau
WT was only detected when co-expressed with ASYN WT
(Fig. 5,C). These findings suggest that the synergistic growth effect
observed upon co-expression of ASYN WT and tau WT in this
integrative model is probably triggered by the high percentage of
ASYN cytoplasmatic inclusions and by the increased fraction of
insoluble tau.
Discussion
Interactions between ASYN and tau have been shown to occur
in several neurodegenerative diseases, as relevant as AD and PD.
Although some light has been shed on the cellular effects resulting
from this interaction [64], a full understanding of the cellular
mechanisms triggered by this toxic duet has not been achieved yet.
In this work two different yeast sets of strains were developed and
characterized with the final aim of being used as tools for the
discovery of potential target genes that mediate the interaction
between ASYN and tau.
We started by promoting the expression of ASYN and tau
isoforms in yeast from a bidirectional episomal vector. Expression
of ASYN isoforms alone led to a cytotoxic growth phenotype, as
reported before [40]. On the contrary, no changes in yeast growth
properties were observed upon expression of tau WT or mutants,
also in accordance with previous observations [43]. In our study,
co-expression of ASYN and tau from a bidirectional episomal
vector resulted in no evident synergistic toxic effect. Previous data
showed that co-expression of tau and ASYN in yeast resulted in
synergistic growth delay [44], although in that case, no cytotoxicity
upon expression of ASYN alone was observed, in clear contrast to
the majority of the published studies.
In our episomal co-expression strains, ASYN levels remained
constant in all the strains analysed, whereas tau levels strongly
decreased upon co-expression with ASYN. The observed reduc-
tion in tau protein levels is not specific to the co-expression of
ASYN. Similar results were observed upon co-expression of tau
and other proteins and most probably reflect a lower protein
expression efficiency resulting from the simultaneous use of the
Gal1-Gal10 divergent promoter and subsequent downstream
processes. ASYN levels were not affected by co-expression of a
second transgene, which might be due to the small size of this
transcript, which allows higher protein expression efficiency.
Overall, co-expression of ASYN and tau had no evident effect
on the size and number of ASYN intracellular inclusions.
Our results showed that the presence of ASYN affected the
solubility of tau, increasing the fraction of insoluble/aggregated
protein, both for tau WT and tau P301L. To further explore this
evidence we analysed tau phosphorylation at Ser396/404, as tau
phosphorylation is known to lead to the formation of insoluble tau
aggregates. Indeed, co-expression of ASYN isoforms with either
tau WT or tau P301L led to a significant increase in tau
phosphorylation, particularly in the case of co-expression of tau
isoforms with ASYN A53T. ASYN has been reported to directly
stimulate tau phosphorylation by GSK3b by making part of a
heterotrimeric complex containing ASYN, tau and GSK3b [30,61].
The pathological epitope Ser396/404 is a typical GSK3b substrate,
already shown to be a target for tau phosphorylation in yeast [42].
We showed that in our model the presence of ASYN led to
increased aggregation of tau through phosphorylation at Ser396/
404 via RIM11, the yeast orthologue of GSK3b. In RIM11-deleted
strain, no phosphorylation at Ser396/404 was observed. To our
knowledge, this is the first evidence that ASYN is able to induce
tau phosphorylation and aggregation in yeast, proving that yeast
recapitulates the reported mechanism through which ASYN
stimulates GSK3b, leading to phosphorylation of tau at pathogenic
epitopes [61].
Despite the increased phosphorylation and aggregation of tau
WT and tau P301L promoted by co-expression of ASYN isoforms,
no synergistic differences in growth phenotype were detected due
to alterations in phosphorylated tau in our episomal yeast strain.
Nevertheless, previous studies in yeast have consistently revealed
that tau expression per se does not affect growth, despite tau
phosphorylation, conformational changes and accumulation into
aggregates [38]. In addition, the precise nature of the toxic tau
species and the exact sequence of events leading to tau-mediated
toxicity are not consensual. Several lines of evidence suggest that
tau aggregates are not the main cause of cell death, as neuron loss
can be observed in the absence of tau tangles in both Drosophila
and mice models [65–67] and other mice models show dissociation
between brain areas of neurofibrillary tangles formation and
neuronal loss [68,69]. Results obtained with our episomal strain
therefore mimic a relevant feature of human neurodegeneration,
although not resulting in a measurable synergistic phenotype of
strains expressing either ASYN (WT or A53T) alone or expressing ASYN WT in combination with tau WT. Tau P301L seems to rescue cytotoxic effect
mediated by ASYN (WT and A53T) as well as tau WT when in combination with ASYN A53T. A quantitative plot of the dot spots is shown (*p,0,05;
***p,0,001). Results are representative of at least three independent experiments. C) Strong growth delay also observed in liquid growth analysis at
30uC upon co-expression of ASYN (WT and A53T) alone or ASYN WT in combination with tau WT. As in solid media tau P301L seems to rescue
cytotoxic effect mediated by ASYN (WT and A53T) as well as tau WT when in combination with ASYN A53T. All results are representative of at least
three independent experiments.
doi:10.1371/journal.pone.0055848.g004
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Figure 5. High percentage of ASYN cytoplasmatic inclusions and insoluble Tau correlate with the observed synergistic growth
effect. A) Percentage of cells showing ASYN intracellular aggregates, detectable by immunofluorescence with anti-ASYN antibody, is similar when
ASYN WT is expressed alone or in combination with tau WT, while when it is in combination with tau P301L it is highly reduced. Co-expression of
ASYN A53T with tau (WT or P301L) also shows a decreased percentage of cells with intracellular aggregates. (*p,0,05; ***p,0,001). For statistical
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growth arrest. Different observations were previously described for
ASYN and tau co-expression in yeast [44]. Nevertheless, the
authors used a different approach, expressing each protein from
an independent episomal plasmid (and thus not allowing for copy
number control and stability). Additionally, tau protein levels and
phosphorylation state were not accessed in the reported study, thus
not allowing a more direct comparison with the results obtained in
the present work.
We next evaluated the co-expression of ASYN and tau isoforms
in yeast by making use of a different experimental approach, based
on the stable integration of one copy of each transgene in the yeast
genome. Our main goal was to achieve higher tau expression
levels, in order to maximize any eventual underlying phenotypic
change. Using this integrative approach, tau protein levels were
found to be constant in all the generated strains, whereas ASYN
levels showed variations. Again, expression of ASYN isoforms
alone caused cytotoxic growth delay, more pronounced in the case
of ASYN A53T. Despite the high and constant expression levels,
the presence of tau isoforms alone had no implication in yeast
growth phenotype.
Yeast strains co-expressing tau P301L with either ASYN
isoform seemed to display a milder phenotype than strains
expressing ASYN isoforms alone. Nevertheless, this ‘‘rescue’’ is
only apparent has it reflects the low levels of ASYN in the yeast
strains co-expressing tau P301L. Accordingly, strains co-expressing
ASYN isoforms with tau P301L display a reduced number of
ASYN inclusions when compared to the strains expressing ASYN
WT or A53T alone. Moreover, these inclusions were predomi-
nantly located at the cell membrane, indicating an early stage of
toxicity [40], as no cytoplasmatic ASYN aggregates were observed.
A strong synergistic effect in yeast growth was observed upon
stable integration and co-expression of ASYN WT and tau WT.
Similar observations were previously reported for the co-expres-
sion of these two proteins from two episomal vectors in yeast [44],
although the typical growth delay upon expression of ASYN alone
did not occur. The synergistic phenotype observed in our study
was associated with increased phosphorylation of tau at Ser396/
404, presumably via RIM11 as a consequence of stimulation by
ASYN. High levels of ASYN intracellular inclusions were present
in this strain, all located in the cytoplasm and thus representative
of late aggregation stages [40]. Most importantly, the yeast strain
expressing ASYN WT and tau WT also showed to display an
increased fraction of insoluble tau. It is known that ASYN toxicity
in yeast is directly correlated to aggregation and inclusion
formation [40,70] and the number of cells which displayed ASYN
inclusions, as well as the localization of those inclusions, were
identical between the strain expressing ASYN WT and the strain
co-expressing ASYN WT and tau WT. As no differences in the
pattern of cytoplasmatic inclusions were registered, the increased
toxic phenotype observed must be triggered by the high
intracellular levels of both proteins, leading to the concomitant
presence of a high number ASYN inclusions and a high amount of
phosphorylated and aggregated tau. Occurrence of a measurable
synergistic growth arrest phenotype was also favoured by the use of
the W303-1A yeast strain, whose genetic background is more
sensitive than the BY4741 yeast strain. With W303-1A, evident
growth delay upon expression of ASYN alone can be observed
already at 30uC (Fig. 4,B) whereas for BY4741 only at 37uC the
same phenotype is achieved (Fig. 1, B). Three mutations
differentiate W303-1A from BY4741: 1) Ybp1-1 mutation which
abolishes Ybp1 function, increasing sensitivity to oxidative stress, 2)
Rad5-G535R missense mutation which abolishes Rad5 function,
involved in DNA repair and 3) Bud4 affecting axial budding [71–
73]. The use of a genetically more sensitive strain, together with
the high levels of ASYN inclusion formation and tau phosphor-
ylation and aggregation favoured the occurrence of a measurable
synergistic cytotoxic phenotype [74].
In summary, our findings demonstrated that for the yeast strains
developed, ASYN directly induced tau phosphorylation in S396/
404 via RIM11 and that formation of tau insoluble aggregates
seemed to be dependent on tau phosphorylation level. Expression
of ASYN, but not tau alone, led to growth retardation and a strong
synergistic growth effect was observed upon genome integration of
ASYN WT and tau WT. Therefore, we have developed yeast
strains that recapitulate many of the most relevant aspects of
ASYN and tau interactions in human pathology. The choice of
yeast as the model organism will allow easy genetic manipulation
for the identification of genes that can modulate the interaction
between ASYN and tau. The episomal and integrative yeast
strains presented here are powerful tools for rapid genome-wide
analysis, allowing the combined development of both yeast
knockout and plasmid overexpression screenings. In particular,
the integrative strain displaying a synergistic toxic phenotype due
to the co-expression of ASYN and tau is the model of choice for
conducting screens in the search for genes that can be future
targets for the development of new therapies for neurodegener-
ative diseases.
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Tau Phosphorylation at S396/404 Mediates the Synergistic 
Cytotoxic Effect 
It is known that tau hyperphosphorylation is an early event leading to the 
formation of NFTs in which hyperphosphorylation at S396/404 is a pathological 
feature [472]. We previously showed that the AD2 tau phospho-epitope was not 
detected in the ΔRIM11 mutant yeast strain, transformed with the inducible high-
copy plasmid expressing tau (WT or P301L) alone or in combination with ASYN 
(WT or A53T) [501]. Thus, to further assess the role of tau phosphorylation at 
S396/404 in the synergistic cytotoxic effect observed, the RIM11 gene was 
removed from the integrative yeast strains expressing ASYN WT and tau WT 
alone or in combination.
The single deletion mutants W303-1A were obtained upon RIM11 replacement 
with the HIS3 gene amplified from p413 GAL1 (ATCC-87326) using the 
following primers: Fw_atgaatattcaaagcaataattctccgaatctcagtaataacaaattcccgtttt 
aagagcttg and Rw_ttacttagacttcggatatagctttttttttacagatgatctacataagaacacctttggtgg. 
W303-1A yeast strains were then transformed with the HIS3 PCR product. Both 
transformation of the yeast strains using the lithium acetate method and 
transformants colony selection were performed as described in [502]. 
Confirmation of HIS3 gene integration was performed by PCR using the 
following primers: Fw_cattacaacacggcaacact and Rw_aaagaaaattgcgggaaagg. As 
expected, western blot analysis revealed that tau phosphorylation at S396/404 is 
strongly reduced if not absent upon removal of RIM11 gene (Figure 23,A). 
Most importantly, growth ability test in solid media showed that absence of tau 
phosphorylation at S396/404 abrogates the synergistic phenotype 
obtained (Figure 23,B), proving that the enhanced cytotoxicity is really 
mediated by the cooperation between ASYN WT and tau WT. These results 
suggest that ASYN mediated hyperphosphorylation of tau at S396/404 might 
give rise to cytotoxic oligomeric tau species, since this synergistic cytotoxicity 
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is only observed in the yeast strain showing the higher level of AD2 phospho 
tau in correlation with the presence of tau in the sarkosyl insoluble 
fraction. Recapitulating, in our integrative yeast model ASYN WT indirectly 
stimulates tau WT phosphorylation at S396/404 via Rim11, promoting its 
fibrillization and enhancing the ASYN mediated cytotoxic effect. 
Figure 23: Tau phosphorylation at S396/404 mediates the synergistic cytotoxic effect. A) 
Strongly reduction or absence of phosphorylated tau WT detected in ΔRIM11 mutants by 
western blot when expressed alone or in combination with ASYN WT. GAPDH was used as 
loading control. B) Lack of tau phosphorylation at S396/404 rescues the synergistic cytotoxicity 
observed in solid media when tau WT and ASYN WT are expressed in combination in ΔRIM11 
as compared to expression in WT yeast strain. A quantitative plot of the dot spots is shown 
(***p<0,001). Results are representative of at least three independent experiments. 
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Abstract
Several reports have proven a consistent overlap between synucleinopathies and tauopathies suggesting that a synergistic neurotoxic 
effect might exist. Alpha-Synuclein (ASYN) was found in neurofibrillary tangles mainly composed by tau protein and tau was also 
found in Lewy bodies mainly composed by ASYN protein. Direct binding between these two proteins has been described and it was 
also confirmed that ASYN can act as a pathological initiator of tau phosphorylation and aggregation. We previously designed and 
characterized a yeast model in which the concomitant expression of the human ASYN and tau proteins is synergistically cytotoxic. 
The model has been used to perform high throughput screening assays (HTS) and genome wide screening assays (GWS) to identify 
compounds and target genes that modulate this interaction, in order to shed light into the pathological mechanism of cell 
dysfunction and to provide new strategies for future therapeutic intervention. By GWS and HTS preliminary screenings we have 
identified 5 different yeast genomic fragments containing a total number of 25 genes and 11 natural extracts able to interfere with the 
ASYN and tau mediated synergistic cytotoxicity. Both genes and extracts identified have the potential to uncover new molecular 
mechanisms that might be targeted for the treatment of patients affected by neurodegeneration. 
Introduction
Synucleinopathies and tauopathies regroup a wide number of 
neurodegenerative disorders in which the presence of insoluble 
proteinacious aggregates generates disease-specific histopathologic 
lesions [1-3]. In tauopathies, one of the major pathological 
hallmarks corresponds to the presence of intracellular protein 
aggregates called neurofibrillary tangles (NFTs). NFTs are 
composed of paired helical filaments (PHF), which comprise 
pathological filamentous aggregations of abnormally 
hyperphosphorylated tau [4-9]. Similarly, in synucleinopathies the 
intraneuronal proteinacious cytoplasmic inclusions termed Lewy 
bodies (LB) are mainly composed by the presynaptic ASYN 
protein [10]. In several reports consistent overlapping between 
synucleinopathies and tauopathies has been reported suggesting 
that a synergistic neurotoxic effect might exist. Notably, direct 
binding between these two proteins was proved, ASYN was found 
within the NFTs and tau was found within LB. Tau 
phosphorylation is also promoted by ASYN enhancing the activity 
of GSK3B and each of these proteins, can act as seeds for the 
aggregation of the other [11-16]. Moreover, in a synucleinopathy 
mammalian model, co-expression of tau enhances ASYN 
aggregation and toxicity [15].
Starting around 1960, S. cerevisiae was introduced as an 
experimental system for molecular biology [17] and in 1996 yeast 
was the first eukaryotic organism for which the complete genomic 
sequence could be established [18,19]. Of the 6000 genes predicted 
to be encoded by its 12000-kb genome [20] about 80% are 
functionally characterized [21-23]. Most importantly, ~30% of 
human genes involved in the development of many human 
diseases have functional homologues in yeast [24]. Yeast cells are 
unicellular microorganisms that are easy to cultivate in large 
populations, in low-cost media and in a partially automated 
manner. Yeast are preferred for high-throughput screening of 
libraries due to advantages such as evaluation of compounds in a 
physiologically relevant environment and immediate negative 
selection of toxic compounds or those with poor membrane 
permeability [25]. 
Heterologous gene expression and genetic manipulations, such 
as insertion, deletion or mutations, are easy to perform [26] and 
several permanently updated online databases have become 
available (e.g. the Saccharomyces Genome Database - SGD; http://
www.yeastgenome.org). Moreover, a collection of single deletion 
mutant strains is available for diploid cells and for non-essential 
genes for haploid cells [27] together with overexpression 
collections based on the yeast genome [28] or single inducible 
ORFs [26,29], providing powerful tools for genome-wide screening 
assays.
Despite the absence of a nervous system, yeast cells have been 
largely used to get insight into neurodegenerative disorders 
[30-32], as many of the pathways involved in pathology 
progression, such as mitochondrial activity, transcriptional 
regulation, intracellular trafficking and protein quality control 
are well conserved among yeast and human [33]. In many 
cases, the human gene encoding the neurodegeneration-
causing protein has no ortholog in yeast. However, the 
heterologous expression of the human gene of interest has been 
widely used originating the so called “humanized yeast” [30,34]. 
In yeast, a synergistic cytotoxic effect upon co-expression of 
ASYN and tau has been already reported, however a detailed 
characterization of this interaction was missing [35]. In our 
previous study, a stable yeast model co-expressing one copy of 
the human wild-type ASYN and one copy of the human wild-
type tau displayed a strong synergistic cytotoxic effect that 
correlates with the presence of intracellular protein aggregates 
composed by ASYN or tau and with increased phospho-tau 
levels at the pathological epitopes S396/404 [36]. Here, we used 
this model to perform a GWS using a “yeast genomic tiling 
collection” and to perform a HTS in order to identify both 
target genes and natural extracts able to interfere with the 
synergistic cytotoxic effect. We obtained a group of 25 potential 
target genes and 11 natural extracts able to rescue the ASYN 
and tau mediated synergistic cytotoxic effect. 
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Materials and Methods
Yeast Strains and Media
In this study was used the W303-1A integrative yeast model 
characterized in [36]. In the HTS assay was used the original 
strains whereas in the GWS assay the LEU2 gene integrated with 
YIpLac128 Gal1 vector was replaced with the HIS3 gene amplified 
from p413 GAL1 (ATCC-87326) using the following primers: Fw 
tcatgacattaacctataaaaataggcgtatcacgaggccaattcccgttttaagagcttg and 
Rw_taaagtttatgtacaaatatcataaaaaaagagaatctttctacataagaacacctttggtgg.  
The yeast strains were then transformed with the HIS3 PCR 
product. Both transformation using the lithium acetate method 
and transformants colony selection were performed as described in 
[37]. Confirmation of HIS3 gene integration was performed by 
PCR using the following primers: Fw_acgaccatcacaccactgaa and 
Rw_tccatcaaatggtcaggtca. All strains were grown in synthetic 
complete media (SC) which consists of 0,67% yeast nitrogen base 
(Sigma-Aldrich), 0,067% yeast drop-out mix (MP Bio) and 2% (w/
v) carbon source glucose, galactose or raffinose, (Sigma-Aldrich)
depending on the experiments, solid media plates also contain 2% 
agar (BD).
Goat Anti-MouseIgG (H+L)-HRP Conjugate (BioRad) diluted 
1:10000 and goat Anti-Rabbit IgG (H+L), Horseradish Peroxidase 
conjugate (Invitrogen) diluted 1:10000, all in TBST containing 1% 
milk. Membranes were revealed using Immobilon Western 
Chemiluminescent HRP Substrate (Millipore) and digital images 
acquired with Alliance 4.7 (UVITECH Cambridge). Quantification 
analysis was performed using ImageJ [38] and statistical 
significance was determined by performing one-way ANOVA with 
post-hoc Dunnett’s test using GraphPad Prism.
High Throughput Screening Assay
The W303-1A integrative control strain (Empty Vectors) and 
the W303-1A integrative target strain (ASYN WT+Tau WT) were 
used for the screening of 3932 LUSOEXTRACT crude extracts. The 
extracts were re-suspended in DMSO and stored in 96-well plates 
at a concentration of 25 mg/ml. All liquid-handling steps were 
performed using a Janus Automated Workstation (PerkinElmer, 
Waltham, MA). Yeast cells were grown in a Liconic STX40 
Automated Incubator and growth was monitored with a Victor 3V 
microplate reader (PerkinElmer). A validation assay was 
performed to confirm the growth profile of the target and control 
strains and asses the robustness of this platform by calculation of 
the Z factor which was 0,79. For the validation and screening assay, 
both strains were pre-grown at 30°C with agitation (200 rpm) in in 
selective SC medium containing raffinose. Then, cultures were 
diluted in selective SC medium containing glucose or galactose to 
OD600 of 0,05 and 96-well plates were filled with 196 µl of culture 
per well (control or target strains). LUSOEXTRACT Crude Set 
extracts were added to the wells containing the target strain at a 
final concentration of 0.5 mg/ml. Plates were then incubated in 
LiCONic STX40 for approximately 68 hours at 30°C and OD600 
was read in Victor 3V microplate reader every 4 hours. Results 
obtained were analyzed with Microsoft Excel, the parameters 
average (AVER), standard deviation (STDEV) and maximum value 
(MAX) were used to determine adequate thresholds for hits 
determination. The threshold chosen for hits determination was: 
MAX + STDEV. Values of OD600 higher than this threshold were 
considered hits. Hit confirmation was performed in a secondary 
dose-response screening at four different concentrations: 0,125 – 
0,25 – 0,5 and 0,75 mg/ml. In this secondary screening the control 
strain was also used for testing the extracts in the highest 
concentration of 0,75 mg/ml. 
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Spotting Assays
Cell growth was analysed on solid selective SC medium to 
maintain selection for plasmids by spot assay by performing 5X 
fold serial dilutions of exponential growing cultures, starting at 
OD600 = 1,0. For this, cells were pre-grown overnight at 30°C with 
agitation (200 rpm) in selective SC medium, containing raffinose. 
After this pre-incubation, cells were re-inoculated in the same 
selective SC medium at OD600 of 0,2 and left to grow at 30°C with 
agitation (200 rpm) until an OD600 of 1,0 was reached. Spot plates 
containing glucose (non-inducing medium) or galactose (inducing 
medium) were incubated at 30°C or 37°C with images being 
acquired after 72 hours of incubation. Quantification analysis was 
performed using ImageJ [38] acquiring the intensity of all the spots 
in each lane from the plates containing galactose and then 
normalized versus the respective values obtained from the control 
plate containing glucose. Statistical significance was determined by 
performing one-way ANOVA with post-hoc Dunnett’s test using 
GraphPad Prism.
Immunoblotting
Immunoblotting was conducted following standard procedures 
[39] with some minor modifications. Yeast cells were pre-grown at 
30°C with agitation (200 rpm) in selective SC medium containing 
raffinose. After this pre-incubation, cells were inoculated at OD600 
of 0,2 in selective SC medium containing galactose with or without 
natural extracts and incubated overnight at 30°C with agitation (200 
rpm). Cells were harvested by centrifugation, washed in sterile 
water and pellets were re-suspended in 100 ml of 1X SDS sample 
buffer (60 mM Tris-HCl pH 6,8, 10% glycerol, 2% SDS, 70 mM β-
ME, 1% bromophenol blue supplemented with 1X protease 
inhibitor cocktail (Sigma-Aldrich) and 1X PhosSTOP (Roche) 
phosphatase inhibitor cocktail). After re-suspension, pellets were 
lyzed by boiling for 5 minutes. 15 µl of each sample was run in a 
12% SDS-PAGE gel and blotted onto PVDF membrane. 
Immunodetection was carried out using the following primary 
antibodies: Total tau (Polyclonal Rabbit anti-Human Tau, Dako) 
diluted 1:10000, ASYN (Purified Mouse Anti-a-Synuclein, BD) 
diluted 1:1000, ANTI_FLAG M1 (Purified Mouse Monoclonal anti-
FLAG epitope, Sigma-Aldrich) diluted 1:3000 and GAPDH (Mouse 
Monoclonal Anti-GAPDH, Ambion) diluted 1:3000, all in in TBST 
containing 1% milk. The following secondary antibodies were used:
Genome Wide Screening Assay
The modified W303-1A integrative control strain (Empty 
Vectors) and the W303-1A integrative target strain (ASYN WT
+Tau WT) were used to perform the GWS assay. In this screening 
we used the Yeast Genomic Tiling Collection Assay Ready DNA 
(Thermo Scientific Cat.YSC5103) which consists of Pooled DNA 
(1588 different clones in suspension) and Empty pGP564 (vector 
control in suspension). According with the product manual the 
control strain was transformed with Empty pGP564 whereas the 
target strain was transformed with the Pooled DNA. High 
efficiency transformation, transformants colonies selection and 
transformation efficiency calculation was executed as described in 
[40] with some minor modification. Transformation: heat shock at 
42°C for 30 minutes followed by 2 hours of recovery at 30°C in 
liquid YPD media (Sigma-Aldrich) before transformants colonies 
selection. Transformants colony selection target strain: 96 hours of 
incubation at 35°C in solid selective SC medium containing 
galactose. The growth ability of target strain transformants colonies 
was then evaluated by spotting assay. From each target strain 
transformants colonies showing growth recovery was extracted the 
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Target Genes Identification by GWS Assay
  In solid media, the previously reported integrative yeast strain co-
expressing ASYN WT and tau WT shows a strong synergistic toxic 
effect at 30°C, whereas total growth arrest is observed at 37°C [36]. 
Our goal now was to identify genes which expression in this model 
would lead to growth recovery, thus eliminating the observed 
toxicity. Transformation of the yeast strain co-expressing ASYN 
and tau with a vector harbouring the gene(s) able to eliminate this 
synergistic effect should lead to growth recovery. The tiling 
collection was transformed into our yeast model, followed by 
incubation in inducible solid media at 35°C. At this intermediate 
temperature, only cells with decreased cytotoxicity are able to 
survive. A total of three transformations resulted in 6 surviving 
colonies showing phenotype rescue by dot spot growth assay 
(Figure 1,A).  In order to rule out a beneficial effect resulting from 
decreased expression of either ASYN or tau, the level of both 
proteins was evaluated by western blot (Figure 1,B). No significant 
differences in ASYN or tau proteins levels were observed for the 6 
colonies that showed growth recovery upon transformation if 
compared with levels of the original yeast strain.
  The plasmids carried by the recovering colonies were extracted 
and sequenced to identify the exact genomic fragments leading to 
phenotype rescue. According to the information provided by the 
tiling collection manufacturer, the 6 selected plasmids 
corresponded to 5 different vectors with a total number of 25 
complete genes. Colonies 5 and 6 were carrying the same plasmid. 
Notably, the 25 genes identified included 4 genes with human 
ortholog, 4 dubious ORFs and 4 genes of unknown function (Table 
2). The other 13 genes encompass many different molecular 
mechanisms ranging from cell wall assembly to gene expression.
  Taking in consideration the gene function and the respective 
intracellular protein localization, 19 coding sequences (CDS) were 
selected for PCR amplification (Table 3). Preference was given to 
the genes having a human ortholog or linked to the typical 
neurodegenerative molecular mechanisms such as DNA damage, 
cell signalling and mitochondria activity.Selected CDS were added 
of a C-terminal FLAG epitope and individually sub-cloned into the 
p413 plasmid under the inducible Gal1 promoter. Each of the 
resulting vectors was then transformed into the yeast strain co-
expressing ASYN and tau and growth ability tests were performed 
in order to identify the genes that, when expressed independently, 
were able to lead to phenotype recovery. Protein expression was 
then evaluated by immunoblotting using the anti-FLAG antibody 
(Figure 2).
  Upon transformation, none of the constructs tested displayed 
beneficial effect for the cell viability (Figure 2,A) and protein 
expression was detectable by immunoblotting only in 8 samples 
(Figure 2,B). To further explore potential beneficial effect of the 
selected CDS that might be related to the protein expression level, 
we also used the constitutive GDP promoter to drive the 
expression of the selected CDS. The CDS of the constructs in 
which protein expression was detectable by immunoblotting were 
sub-cloned into the p413 GPD vector and transformed into the 
yeast strain co-expressing ASYN and tau. Again, by growth ability 
test no phenotype recovery was observed and protein expression 
was detectable in all the samples tested except in the strain 
transformed with the vector carrying the EXG2 CDS (data not shown). 
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contained plasmid (Qiagen, Plasmid Mini Kit) and then sequenced 
to identify the genomic fragments carried by each clone. The 
selected CDS of the corresponding genes identified upon 
sequencing were then amplified by PCR, C-terminal FLAG epitope 
tagged and cloned into the p413 Gal1 or GPD (ATCC-87326; 
87354) using the following primers (Table 1). Both ttransformation 
of yeast the strains with the resultants p413 vectors and 
transformants colony selection were performed using the lithium 
acetate method as described in [37].
Table 1: Sequences of the primers used for the single CDS cloning and 
respective cloning sites. 
Results
To identify potential target genes able to interfere with the 
synergistic toxic effect mediated by the concomitant expression of 
ASYN and tau we used the “Yeast Genomic Tiling Collection Assay 
Ready DNA”. The collection consists of over 1500 clones each 
containing a unique segment of the yeast S. cerevisiae genome in an 
E. coli-yeast shuttle vector provided as DNA pooled into one single 
tube. These plasmid clones represent a unique and virtually 
complete overlapping clone collection of the entire S. cerevisiae 
genome. This clone collection constitutes a “minimal functional 
pathway” through the yeast genome and represents ~97% of the 
length of the yeast genome at the physical level and ~95% of the 
genome at the functional level [28].
Our first experimental approach to validate the single genes 
responsible for growth recovery was non successful and for many 
of the constructs tested protein expression was not detectable by 
anti-FLAG immunoblotting. However, these preliminary results 
suggest that to validate our data we might need to use other kind of 
constructs more similar to the collection vector in order to have an 
appropriate and functional protein expression. 
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Figure 1: Transformants colonies viability assay. A) Six surviving colonies showing phenotype rescue by dot spots were identified upon transformation of 
the strain co-expressing ASYN WT and tau WT with the tiling collection. B) ASYN and tau protein levels remain similar between the reference strain (ASYN 
WT+Tau WT) alone or transformed with the tiling collection. The GAPDH level is increased in the Col1 as this strain is carrying the tiling collection vector 
containing the TDH3 gene, the yeast ortholog of the human GAPDH (Table 1). Results are representative of three independent experiments.
Table 2: Tiling collection vector identification. Upon sequencing 5 different vectors were identified with a total number of 25 complete genes, included 4 
genes with human ortholog, 4 dubious ORFs and 4 genes of unknown function.
Table 3: Genes individually tested. Summary of the individually cloned genes, intracellular protein localization, functions and promoters tested.
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Figure 2: Screening viability assay. A) No phenotype rescue observed by dot spots upon transformation of the strain co-expressing ASYN WT and tau WT 
with the p413 Gal1 vector harbouring the 19 selected CDS. B) Protein expression was detectable by anti-FLAG immunoblotting only in 8 samples (in red), 
* corresponds to an unspecific band. Results are representative of three independent experiments.
Target Genes Identification by GWS Assay
Since our integrative yeast strain co-expressing ASYN and tau 
shows a strong and reproducible growth delay both in solid and 
liquid media [36], the model was also used to perform an HTS 
assay to identify natural extracts able to interfere with the observed 
synergistic toxic effect. The test collection was LUSOEXTRACT, a 
Portuguese natural heritage composed of 1206 organisms isolated 
from unique Portuguese terrestrial and aquatic ecosystems. From 
this collection, 1016 are microorganisms and 190 are marine 
invertebrates. All organisms that constitute the LUSOEXTRACT 
collection were obtained from collaborations between Bioalvo and 
the major Portuguese Universities and research centers, such as 
Faculdade de Ciências da Universidade de Lisboa (FCUL), 
Faculdade de Ciências e Tecnologia da Universidade Nova de 
Lisboa (FCT-UNL), Centro de Ciências do Mar da Universidade 
do Algarve (CCMAR), Universidade de Aveiro (UA), Faculdade de 
Ciências da Universidade do Porto (FCUP) and Instituto de 
Biologia Molecular e Celular (IBMC). A total of 3932 crude 
extracts were tested in this screening: 1094 methanol extracts, 942 
dichloromethane extracts, 916 hexane extracts, 240 water extracts 
and 740 ethyl acetate extracts.
The integrative yeast strain co-expressing ASYN WT and tau 
WT (target) was used for the screening of the 3932 extracts. The 
target strain was grown in 96-well plates with 200 µl of liquid 
media at 30°C and, as expected, displayed a marked growth delay 
in comparison with the control strain carrying empty the vectors 
(control) (Figure 3). The goal of the screening was to identify 
natural extracts able to restore the growth of the target strain to 
levels closer to the ones of the control strain. The threshold OD600 
value defined for classifying extracts as hits was: MAX + STDEV. 
MAX represents the maximum OD600 value measured of the 
target strain and STDEV is the standard deviation of all the OD600 
values of the same strain. The time point chosen for hits picking 
was 60 hours, at this time the probability to pick false positive 
extracts is very poor as the control strain is already in stationary 
phase, the target strain is growing slowly and the threshold value is 
stable. Extracts resulting in OD600 value at 60 hours higher than 
this threshold were considered as hits (Figure 3). The Z factor 
calculated in the validation assay had a value of 0,79, which reflects 
the robustness of the platform and validates our system as a potent 
tool for HTS.
In the primary screening assay the LUSOEXTRACT crude 
extracts were added to the wells containing the target strain at a 
final concentration of 0,5 mg/ml and upon data analysis a total of 
38 extracts out of the 3932 tested were classified as hits. In the 
secondary screening, the identified hits were re-tested in a 
confirmatory dose-response assay using four different final 
concentrations: 0,125 - 0,25 - 0,5 and 0,75 mg/ml. In this assay the 
control strain was used to test the hits at the higher concentration 
of 0,75 mg/ml in order in order to identify (and subsequently 
exclude) eventual false positives able to enhance the growth of 
yeast strains. Results obtained were analysed according to the same 
parameters used in the primary screening and 17 out of the 38 hits 
identified in the primary screening were re-confirmed. However, 4 
hits also increased the growth of the control strain, thus they were 
excluded from the final readout which consists in 13 confirmed 
hits. To classify the hits, a ranking was established: very good (hits 
showing growth recovery for at least three concentrations), good 
(hits showing growth recovery for two concentrations) and weak 
(hits showing growth recovery for only one concentration) (Table 
4). In order to rule out a beneficial effect on cell growth resulting 
from decreased expression of either ASYN or tau, the level of both 
proteins in yeast cells treated with the hit extracts was evaluated by 
western blot. No significant differences in ASYN or tau proteins 
levels were observed upon treatment with most of the extracts that 
showed growth recovery. However, a slight decrease in ASYN 
protein level was observed in the samples treated with extracts N°9 
and N°13 (Figure 4).
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Figure 3: Example of a hit identification. The threshold chosen for hits 
determination was calculated as MAX + STDEV at 60 hours. Extracts 
resulting in OD600 values at 60 hours higher than this threshold were 
considered as hits.
Figure 4: Protein expression analysis of the target strain treated with the hit extracts. ASYN and tau protein level remains constant in the samples threated 
with the extracts identified as hits at 0.5 mg/ml. Exception was observed upon treatment with the extracts N°9 and N°13 that showed a slight decrease in the 
ASYN protein level.
Table 4: Extracts re-confirmed as hits. Summary of the hits identified the 
corresponding organism, specie and ranking.
Interestingly, two of the confirmed hits correspond to extracts 
of Calliactis parasitica that produces neurotoxins such as Cpl and 
Calitoxin (CLX) [41,42]. Other relevant specie, Rhodopirelulla 
baltica, is able to degrade sulphated polymeric carbon in the 
marine environment [43]. Thus, our HTS resulted in 11 confirmed 
natural extracts hits coming from the unique Portuguese 
LUSOEXCTRAC collection, that have the potential to be further 
explored in other ASYN-tau disease related models
Discussion
Synucleinopathies and tauopathies regroup a wide number of 
neurodegenerative disorders such as AD and PD [1-3]. 
Synucleinopathies are characterized by the presence of Lewy 
bodies mainly composed by the presynaptic ASYN protein [10] 
whereas the pathological hallmark of tauopathies consists in the 
presence of neurofibrillary tangles positive for 
hyperphosphorylated tau protein [4-6]. Interactions between 
ASYN and tau have been shown to occur in several 
neurodegenerative disease models, suggesting that a synergistic 
neurotoxic effect might exist [11-16]. However, the mechanisms 
leading to cell death related to ASYN and tau interactions are still 
elusive. Yeast cells have been proven to be a powerful model to get 
insight into neurodegenerative disorders [30-32] and are largely 
used in genome-wide screening and high-throughput screening 
assay [24-29]. In our previous study we developed and 
characterized a stable yeast model in which the co-expression of 
the human ASYN and tau protein is synergistically cytotoxic [36]. 
Here, we used this model to perform a GWS and HTS assays 
in order to identify both target genes and natural extracts able to 
interfere with the cytotoxic effect observed.
The GWS assay was performed in solid media using the “Yeast 
Genomic Tiling Collection Assay Ready DNA” consisting of about 
1500 clones, each containing a unique segment of the yeast S. 
cerevisiae genome in an E. coli-yeast shuttle vector provided as 
DNA pooled into one single tube [28]. Upon transformation of the 
yeast strain co-expressing ASYN and tau with the collection pooled 
clones, we were able to identify 6 surviving colonies showing 
phenotype recovery. The phenotype rescue was an effect completely 
mediated by the overexpression of S. cerevisiae genomic fragments 
and thus linked to the genes contained into, since the protein 
expression levels of ASYN and tau remained comparable between 
the yeast strains with or without collection vectors. To identify the 
genomic fragment contained in each surviving colony we extracted 
and sequenced the respective vectors. Data analysis revealed 5 
different genomic fragments with a total number of 25 complete 
genes. To further validate our results discovering the genes 
responsible for growth recovery we decided to test individually 
each single gene and considering the gene function and cellular 
localization we selected 19 primary target CDS. We started the 
validation by cloning the selected FLAG-tagged CDS in a new 
vector under the inducible Gal1 or constitutive GPD promoter. 
However upon transformation none of the constructs tested 
showed growth recovery and in most of the samples protein 
expression was not detectable by anti-FLAG immunoblotting. 
These preliminary results suggest that to have a functional 
protein expression, comparable with the collection vector, and 
thus observe growth recovery, we might need to use other constructs
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7harbouring the endogenous promoter in combination with the 
respective complete ORF.   It is also plausible that the phenotype 
rescue could be mediated not only by one single gene but it might 
be the resultant of cooperation between two or more genes carried 
in the same collection vector. However, the identification of 
genomic fragments that, when overexpressed, are able to strongly 
increase the cells lifespan, deserves further attention to uncover 
new genes and pathways that might be targeted for the treatment of 
neurodegenerative disorders.
The high stability of our model in combination with a 
reproducible strong growth delay also in liquid media [36], allowed 
us to perform a HTS assay using our in house LUSOEXCTRACT 
collection. The aim of the screening was to identify natural extracts 
able to enhance the cell growth of the yeast strain co-expressing the 
ASYN and tau protein. The screening was performed using an 
automated workstation and divided in two steps. In the first step 
the natural extracts were tested in a single dose and upon data 
analysis a total number of 38 extracts out of the 3932 tested were 
classified as hits. In the second step the 38 hits were re-tested in a 
confirmatory dose-response assay and data analysis resulted in 13 
confirmed hits. A further validation assay was than performed to 
evaluate if the growth recovery resulted from decreased ASYN or 
tau protein expression levels and a slight decrease in ASYN protein 
level was observed in the samples treated with 2 out of the 13 
confirmed hits. The final readout of our HTS assay resulted in 11 
natural extracts able to alleviate the cytotoxic effect mediated by the 
concomitant expression of the human ASYN and tau proteins.
In summary, the high phenotype reproducibility makes our yeast 
model a powerful tool to perform various preliminary screening 
assays. In this study, the model versatility allowed us to identify a 
group of 25 potential target genes and 11 natural extracts, coming 
from organisms isolated from unique Portuguese terrestrial and 
aquatic ecosystems, which might be relevant for future therapeutic 
intervention strategies.
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Chapter III. General discussion, Future 
Perspectives and Conclusions 
1. Discussion
In the last century the number of people affected by neurodegenerative 
disorders causing dementia in developed and developing countries is increasing 
year after year, mainly as consequence of increased life expectancy [1-3]. The 
term synucleinopathies regroups different neurodegenerative disorders 
characterized by the presence of insoluble fibrillary aggregates of ASYN protein, 
called Lewy bodies. This group of disorders includes Parkinson’s disease, many 
cases of Alzheimer’s disease (called Lewy bodies variant of Alzheimer’s 
disease), Multiple System Atrophy, dementia with neurofibrillary tangles, 
neurodegeneration with brain iron accumulation type I, pure autonomic failure 
and a subtype of essential tremor [194,195]. Likewise, the term tauopathies 
represent another group of neurodegenerative disorders also characterized by the 
presence of neurofibrillary tangles labelling positive for tau protein [62]. 
Pathologies such as Alzheimer’s disease, frontotemporal lobar degeneration, 
progressive supranuclear palsy and corticobasal degeneration are all examples of 
tauopathies [62]. Taken together, synucleinopathies and tauopathies account for 
about 70% of diseases causing dementia [1-3]. The indication of a potential 
synergistic neurotoxic effect between synucleinopathies and tauopathies rised up 
when in patients’ brains ASYN was found within neurofibrillary tangles and tau 
within Lewy bodies [473-478]. Further investigations demonstrated a direct 
binding between ASYN and tau and the ability to promote each other’s 
fibrillization [250,324,479-481]. Most importantly a synergistic cytotoxic effect 
upon co-expression of ASYN and tau has been reported both in mammalian and 
yeast models [347,482]. 
Given the devastating nature of neurodegenerative disorders and the lack of 
causal therapies, there is great need for finding effective treatments. Uncovering 
novel targets in the continuous search for new therapeutic treatments will enable 
us to move forward towards the development of more effective therapies against 
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the devastating disorders affecting the nervous system. In the work described in 
this thesis, we used yeast as a model system to reproduce and characterize the 
synergistic cytotoxic effect mediated by the co-expression of the human ASYN 
and tau proteins. The model was then used as a tool for the discovery of genes 
and compounds that mediate the toxic interaction between ASYN and tau 
opening up new targets for therapeutic intervention.
We started by promoting the expression of ASYN and tau in yeast from a 
bidirectional episomal vector. Our results showed that the presence of ASYN 
affected the solubility of tau increasing the fraction of insoluble/aggregated 
protein. Since tau phosphorylation is known to lead to the formation of insoluble 
tau aggregates and the pathological phospho-epitope S396/404 is a typical 
GSK3B substrate, already shown to be a target for tau phosphorylation in yeast, 
we analysed the tau phosphorylation at this specific epitope [470,503-507]. We 
showed that the presence of ASYN leads to increased tau phosphorylation at 
S396/404 via Rim11, the yeast ortholog of GSK3B. However, despite the 
enhanced phosphorylation and aggregation of tau promoted by co-expression of 
ASYN, no evident synergistic toxic effect was detected in this yeast strain.  
Looking for a synergistic cytotoxicity, we next evaluated the co-expression of 
ASYN and tau making use of a different experimental approach, based on the 
stable integration of one copy of each human transgene in the yeast genome. In 
this strain was achieved a strong synergistic toxic effect in yeast growth in 
association with the presence of insoluble/aggregated tau and increased 
phosphorylation of tau at S396/404 via Rim11 as a consequence of stimulation 
by ASYN. Importantly, the synergistic cytotoxicity is abrogated upon RIM11 
removal, thus validating our double transgenic model. Our results suggest that the 
synergistic cytotoxic effect might be the resultant of enhanced ASYN mediated 
tau phosphorylation at S396/404 that might give rise to potential cytotoxic 
oligomeric tau species. This is the first evidence that ASYN is able to induce tau 
phosphorylation and aggregation in yeast, proving that yeast 
recapitulates the reported mechanism through which ASYN stimulates 
GSK3B leading to phosphorylation of tau at pathogenic epitopes [484,485]. 
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The yeast models presented here are powerful tools for rapid screening assays. In 
particular the integrative double transgenic yeast strain showing a strong 
synergistic toxic effect both in solid and liquid media was used to perform GWS 
and HTS assays to identify genes and compounds able to modulate the cytotoxic 
interactions between ASYN and tau proteins.
The GWS assay was performed using the “Yeast Genomic Tiling Collection 
Assay Ready DNA” consisting of about 1500 clones, each containing a unique 
segment of the yeast S. cerevisiae genome in an E. coli-yeast shuttle vector 
provided as DNA pooled into one single tube [495]. The screening resulted in 
the selection of 5 different S. cerevisiae genomic fragments that, when 
over-expressed, are able to increase the cells lifespan. Within these fragments a 
total number of 25 different complete genes have been identified. We next 
tried to discover the genes that, when expressed independently, were 
responsible for growth recovery. However, our first experimental approach was 
not successful as none of the single gene tested showed growth recovery 
and in most of the samples protein expression was not detectable. In this step, 
it is plausible that we might use other kind of constructs more similar to the 
collection vector in order to have an appropriate functional protein expression 
and thus growth recovery. It is also plausible that the phenotype rescue could 
be mediated not only by one single gene but it might be the resultant of 
cooperation between two or more genes carried in the same collection vector.  
The high stability of our model in combination with a reproducible strong growth 
delay also in liquid media, allowed us to perform a HTS assay using our in house 
LUSOEXCTRACT collection. This collection is a Portuguese natural heritage 
consisting in 3932 natural extracts coming from 1206 organisms isolated in the 
unique Portuguese terrestrial and aquatic ecosystems. The screening was divided 
in two steps. In the first step the natural extracts were tested in a single dose and 
upon data analysis a total number of 38 extracts were classified as hits. In the 
second step the hits were re-tested in a confirmatory dose-response assay and 
data analysis resulted in 13 confirmed hits. A further validation assay was than 
performed to evaluate if the growth recovery resulted from decreased ASYN or 
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tau protein expression levels. The final readout resulted in 11 natural extracts 
able to alleviate the cytotoxic effect mediated by the concomitant expression of 
the human ASYN and tau proteins. 
In summary, the power of our yeast model allowed us to perform both GWS and 
HTS assays. The identification of genomic fragments that, when overexpressed, 
are able to strongly enhance the cells resistance to the ASYN and tau mediated 
cytotoxicity deserves further attention to uncover new genes and pathways that 
might be targeted for the treatment of neurodegenerative disorders. On the other 
hand, the 11 natural extracts confirmed as hits have the potential to be further 
explored in other ASYN-tau disease related models and developed to be used in 
the pharmacological treatments of patients affected by neurodegeneration. 
2. Conclusions
Neurodegenerative brain diseases constitute a major health problem in 
Europe, and their impact on public health and society is increasing with the aging 
of the population. Various cellular and animal models of synucleinopathies and 
tauopathies have been created, showing neuronal and neurological dysfunction or 
emulating the physiopathology of neurodegenerative disorders. Despite these 
important insights, significant gaps in our understanding on ASYN and tau 
interactions and their relationship to the diseases progression still exist. 
Currently, there are no causal treatments available for PD, AD and other 
synucleinopathies or tauopathies. Therefore, novel therapeutic strategies need to 
be developed for these disease states.  
Budding yeast have been successfully used to perform studies on 
neurodegenerative disorders that have resulted in the identification of several 
promising therapeutic drugs and targets. In this study we developed a yeast based 
screening platform to identify both genes and natural extracts able to interfere 
with synergistic cytotoxic effects mediated by the interaction of ASYN and tau. 
The identifications of modulators of ASYN and tau mediated synergistic toxicity 
might be not only relevant for academic groups working on neurodegeneration, 
but also for companies engaged in CNS drug discovery. Hopefully, our work will 
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impact patients, their families and care-takers significantly, however, would 
certainly need at least another 10 years to reach the patients. 
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